

1/26/2022

## 1) Personal Information:

**Wanda K. O'Neal, Ph.D.**

Research Associate Professor

### OFFICE ADDRESS:

Marsico Lung Institute/ Cystic Fibrosis Center

7212 Marsico Hall, CB # 7248

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina 27599-7248

Phone: (919) 962-9866

FAX: (919) 966-6821

Email: [woneal@med.unc.edu](mailto:woneal@med.unc.edu)

## 2) Education:

Doctor of Philosophy  
1993

**Baylor College of Medicine** - Department of Molecular and Human Genetics, Houston, Texas

Master of Science  
1987

**North Dakota State University**  
Crop Science Department, Fargo, North Dakota

Bachelors of Science  
1984

**North Dakota State University**  
Plant Pathology and Crop Science, Fargo, North Dakota

## 3) Professional Employment and Employment History:

2002-Present

**Research Associate Professor and Director of Molecular Biology Core Laboratory** CF/Pulmonary Research and Treatment Center, Department of Medicine, University of North Carolina at Chapel Hill

1998-2002

**Research Assistant Professor and Director of Molecular Biology Core Laboratory** - CF/Pulmonary Research and Treatment Center, Department of Medicine, University of North Carolina at Chapel Hill

1997-1998

**Assistant Professor** - Department of Molecular and Human Genetics  
Baylor College of Medicine, Houston, Texas

1993-1997

**Postdoctoral Fellow** - Supervising Professor: Arthur L. Beaudet, M.D.  
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. Development of Adenovirus Vectors for Gene Therapy with Emphasis on Treatment of Genetic Disorders of the Lung and Liver

1988-1993

**Graduate Student** - Advisor: Arthur L. Beaudet, M.D.  
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. Thesis Title: "Generation and Characterization of a Murine Model for Cystic Fibrosis."

1984-1987

**Master's Degree Student and Graduate Teaching Fellow**  
Advisor: Calvin Messersmith, Ph.D., Department of Crop Science.  
North Dakota State University, Fargo, North Dakota

## 4) Honors:

None

## 5) Bibliography and Products of Scholarship.

***Published Refereed Papers/Articles (from newest to oldest)***

1. Carpenter J, Wang Y, Gupta R, Li Y, Haridass P, Subramani DB, Reidel B, Morton L, Ridley C, **O'Neal WK**, Buisine MP, Ehre C, Thornton DJ, Kesimer M. 2021. Assembly and organization of the N-terminal region of mucin MUC5AC: Indications for structural and functional distinction from MUC5B. *Proc Natl Acad Sci U S A*. 118(39):e2104490118. PMID: 34548396. PMCID: PMC8488587.
2. Dunican EM, Elicker BM, Henry T, Gierada DS, Schiebler ML, Anderson W, Barjaktarevic I, Barr RG, Bleecker ER, Boucher RC, Bowler RP, Christenson SA, Comellas A, Cooper CB, Couper D, Criner GJ, Dransfield M, Doerschuk CM, Drummond MB, Hansel NN, Han MK, Hastie AT, Hoffman EA, Krishnan JA, Lazarus SC, Martinez FJ, McCulloch CE, **O'Neal WK**, Ortega VE, Paine R 3rd, Peters S, Schroeder JD, Woodruff PG, Fahy JV. 2021. Mucus plugs and emphysema in the pathophysiology of airflow obstruction and hypoxemia in smokers. *Am J Respir Crit Care Med*. 203(8):957-968. PMID: 33180550. PMCID: PMC8048745.
3. Eastman AC, Pace RG, Dang H, Aksit MA, Vecchio-Pagán B, Lam AN, **O'Neal WK**, Blackman SM, Knowles MR, Cutting GR. 2021. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR. *J Cyst Fibros*. 20(5):851-856. PMID: 33674211. PMCID: PMC8410892.
4. Esther CR Jr, **O'Neal WK**, Anderson WH, Kesimer M, Ceppe A, Doerschuk CM, Alexis NE, Hastie AT, Barr RG, Bowler RP, Wells JM, Oelsner EC, Comellas AP, Tesfaigzi Y, Kim V, Paulin LM, Cooper CB, Han MK, Huang YJ, Labaki WW, Curtis JL, Boucher RC; SPIROMICS. 2021. Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in Chronic Obstructive Pulmonary Disease. *Chest*. Epub ahead of print. PMID: 34801592.
5. Fortis S, Comellas A, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R 3rd, Ronish B, Kanner RE, Dransfield M, Hoesterey D, Buhr RG, Barr RG, Dolezal B, Ortega VE, Drummond MB, Arjomandi M, Kaner RJ, Kim V, Curtis JL, Bowler RP, Martinez F, Labaki WW, Cooper CB, **O'Neal WK**, Criner G, Hansel NN, Krishnan JA, Woodruff P, Couper D, Tashkin D, Barjaktarevic I. 2021. Ratio of Forced Expiratory Volume in 1 second /Slow Vital Capacity (FEV1/SVC)<0.7 is associated with clinical, functional, and radiologic features of obstructive lung disease in smokers with preserved lung function. *Chest*. 160(1):94-103. PMID: 33539837. PMCID: PMC8295909.
6. Israel E, Denlinger LC, Bacharier LB, LaVange LM, Moore WC, Peters MC, Georas SN, Wright RJ, Mauger DT, Noel P, Akuthota P, Bach J, Bleecker ER, Cardet JC, Carr TF, Castro M, Cinelli A, Comhair SAA, Covar RA, Alexander LC, DiMango EA, Erzurum SC, Fahy JV, Fajt ML, Gaston BM, Hoffman EA, Holguin F, Jackson DJ, Jain S, Jarjour NN, Ji Y, Kenyon NJ, Kosorok MR, Kraft M, Krishnan JA, Kumar R, Liu AH, Liu MC, Ly NP, Marquis MA, Martinez FD, Moy JN, **O'Neal WK**, Ortega VE, Peden DB, Phipatanakul W, Ross K, Smith LJ, Szeffler SJ, Teague WG, Tulchinsky AF, Vijayanand P, Wechsler ME, Wenzel SE, White SR, Zeki AA, Ivanova A. 2021. PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. *J Allergy Clin Immunol*. 147(5):1594-1601. PMID: 33667479. PMCID: PMC8113113.
7. Morrison CB, Shaffer KM, Araba KC, Markovetz MR, Wykoff JA, Quinney NL, Hao S, Delion MF, Flen AL, Morton LC, Liao J, Hill DB, Drumm ML, **O'Neal WK**, Kesimer M, Gentsch M, Ehre C. 2021. Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration. *Eur Respir J*. Epub ahead of print. PMID: 34172469.
8. Radicioni G, Ceppe A, Ford AA, Alexis NE, Barr RG, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kanner RE, Martinez FJ, Ozkan E, Paine R 3rd, Woodruff PG, **O'Neal WK**, Boucher RC, Kesimer M. 2021. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. *Lancet Respir Med*. 9(11):1241-1254. PMID: 34058148. PMCID: PMC8570975.
9. Okuda K, Dang H, Kobayashi Y, Carraro G, Nakano S, Chen G, Kato T, Asakura T, Gilmore RC, Morton LC, Lee RE, Mascenik T, Yin WN, Barbosa Cardenas SM, O'Neal YK, Minnick CE, Chua M, Quinney NL, Gentsch M, Anderson CW, Ghio A, Matsui H, Nagase T, Ostrowski LE, Grubb BR, Olsen JC, Randell SH, Stripp BR, Tata PR, **O'Neal WK**, Boucher RC. 2021. Secretory Cells Dominate Airway CFTR Expression and Function in Human Airway Superficial Epithelia. *Am J Respir Crit Care Med*. 203(10):1275-1289. PMID: 33321047. PMCID: PMC8456462.

10. Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, Graham Barr R, Bleecker ER, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper DJ, Doerschuk CM, Dransfield MT, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kaner RJ, Krishnan J, **O'Neal WK**, Ortega VE, Paine R 3rd, Peters SP, Michael Wells J, Woodruff PG, Martinez FJ, Curtis JL, Huffnagle GB, Huang YJ. 2021. Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. *NPJ Biofilms Microbiomes*. 7(1):14. PMID: 33547327. PMCID: PMC7865064.
11. Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciruba FC, Zhang Y, Ortega VE, **O'Neal WK**, Gillenwater LA, Lynch DA, Hoffman EA, Newell JD Jr, Comellas AP, Castaldi PJ, Miller BE, Pouwels SD, Hacken NHTT, Bischoff R, Klont F, Woodruff PG, Paine R, Barr RG, Hoidal J, Doerschuk CM, Charbonnier JP, Sung R, Locantore N, Yonchuk JG, Jacobson S, Tal-Singer R, Merrill D, Bowler RP. 2021. Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD. *Respir Res*. 22(1):127. PMID: 33906653; PMCID: PMC8076883.
12. Xu J, Livraghi-Butrico A, Hou X, Rajagopalan C, Zhang J, Song J, Jiang H, Wei HG, Wang H, Bouhamdan M, Ruan J, Yang D, Qiu Y, Youming X, Barrett RP, McClellan SA, Mou H, Wu Q, Chen X, Rogers TD, Wilkinson KJ, Gilmore RC, Esther CR Jr, Zaman K, Liang X, Sobolic M, Hazlett L, Zhang K, Frizzell RA, Gentzsch M, **O'Neal WK**, Grubb BR, Chen YE, Boucher RC, Sun F. 2021. Phenotypes of CF rabbits generated by CRISPR/Cas9-mediated disruption of the CFTR gene. *JCI Insight*. 6(1):e139813. PMID: 33232302. PMCID: PMC7821608.
13. Dang H, Polineni D, Pace RG, Stonebraker JR, Corvol H, Cutting GR, Drumm ML, Strug LJ, **O'Neal WK**, Knowles MR. 2020. Mining GWAS and eQTL data for CF lung disease modifiers by gene expression imputation. *PLoS One*. 15(11):e0239189. PMID: 33253230. PMCID: PMC7703903.
14. Gillenwater LA, Pratte KA, Hobbs BD, Cho MH, Zhuang Y, Halper-Stromberg E, Cruickshank-Quinn C, Reisdorph N, Petrache I, Labaki WW, **O'Neal WK**, Ortega VE, Jones DP, Uppal K, Jacobson S, Michelotti G, Wendt CH, Kechris KJ, Bowler RP. 2020. Plasma Metabolomic Signatures of Chronic Obstructive Pulmonary Disease and the Impact of Genetic Variants on Phenotype-Driven Modules. *Netw Syst Med*. 3(1):159-181. PMID: 33987620; PMCID: PMC8109053.
15. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinno III KH, Kato T, Lee RE, Yount BL, Mascenik TM, Chen G, Olivier KN, Ghio A, Tse LV, Leist SR, Gralinski LE, Schäfer A, Dang H, Gilmore R, Fulcher L, Livraghi-Butrico A, Nicely NI, Cameron M, Cameron C, Kelvin DJ, de Silva A, Margolis DM, Markmann A, Bartelt L, Zumwalt R, Martinez FJ, Salvatore SP, Borczuk A, Tata PR, Sontake V, Kimple A, Jaspers I, **O'Neal WK**, Randell SH, Boucher RC, Baric RS. 2020. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. *Cell*. 182(2):429-446.e14. PMID: 32526206; PMCID: PMC7250779.
16. Kato T, Hiraishi Y, Kaseda K, Suzuki S, Tanaka G, Yamauchi Y, Yasui M, Shinozaki-Ushiku A, Ushiku T, Yamaji O, **O'Neal WK**, Nagase T. 2020. A 79-year-old man with progressive dyspnea and multiple pulmonary nodules. *Chest*. 158(2):e79-e84. PMID: 32768080.
17. Kim V, Jeong S, Zhao H, Kesimer M, Boucher RC, Wells JM, Christenson SA, Han MK, Dransfield M, Paine R 3rd, Cooper CB, Barjaktarevic I, Bowler R, Curtis JL, Kaner RJ, O'Beirne SL, O'Neal WK, Rennard SI, Martinez FJ, Woodruff PG. 2020. Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects. *Sci Rep*. 10(1):20133. PMID: 33208859; PMCID: PMC7674445.
18. McCarron A, Cmielewski P, Reyne N, McIntyre C, Finnie J, Craig F, Rout-Pitt N, Delhove J, Schjenken JE, Chan HY, Boog B, Knight E, Gilmore RC, **O'Neal WK**, Boucher RC, Parsons D, Donnelley M. 2020. Phenotypic characterization and comparison of cystic fibrosis rat models generated using CRISPR/Cas9 gene editing. *Am J Pathol*. 190(5):977-993. PMID: 32084371.
19. Mock JR, Dial CF, Tune MK, Gilmore RC, **O'Neal WK**, Dang H, Doerschuk CM. 2020. Impact of regulatory T cells on type 2 alveolar epithelial cell transcriptomes during resolution of acute lung injury and contributions of IFN- $\gamma$ . *Am J Respir Cell Mol Biol*. 63(4):464-477. PMID: 32543909. PMCID: PMC7528916.
20. **O'Neal WK**, Ribeiro CMP. "Shocking the system" to achieve efficient gene targeting in primary human airway epithelia. 2020. *Am J Respir Cell Mol Biol*. 62(3):279-280. PMID: 31633992. PMCID: PMC7055690.

21. Ortega VE, Li X, **O'Neal WK**, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, Barr RG, Cooper C, Couper D, Han MK, Kanner RE, Kleerup EC, Martinez FJ, Paine Iii R, Peters SP, Pirozzi C, Rennard SI, Woodruff PG, Hoffman EA, Meyers DA, Bleecker ER; NHLBI Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS). 2020. The effects of rare SERPINA1 variants on lung function and emphysema in SPIROMICS. *Am J Respir Crit Care Med*. 201(5):540-554. PMID: 31661293. PMCID: PMC7047460.
22. Putcha N, Fawzy A, Matsui EC, Liu MC, Bowler RP, Woodruff PG, **O'Neal WK**, Comellas AP, Han MK, Dransfield MT, Wells JM, Lugogo N, Gao L, Talbot CC 2nd, Hoffman EA, Cooper CB, Paulin LM, Kanner RE, Criner G, Ortega VE, Barr RG, Krishnan JA, Martinez FJ, Drummond MB, Wise RA, Diette GB, Hersh CP, Hansel NN. 2020. Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene. *Chest*. 158(6):2333-2345. PMID: 32450244. PMCID: PMC7768932.
23. Raffield LM, Dang H, Pratte KA, Jacobson S, Gillenwater LA, Ampleford E, Barjaktarevic I, Basta P, Clish CB, Comellas AP, Cornell E, Curtis JL, Doerschuk C, Durda P, Emson C, Freeman CM, Guo X, Hastie AT, Hawkins GA, Herrera J, Johnson WC, Labaki WW, Liu Y, Masters B, Miller M, Ortega VE, Papanicolaou G, Peters S, Taylor KD, Rich SS, Rotter JI, Auer P, Reiner AP, Tracy RP, Ngo D, Gerszten RE, **O'Neal WK**, Bowler RP; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. 2020. Comparison of proteomic assessment methods in multiple cohort studies. *Proteomics*. 20(12):e1900278. PMID: 32386347; PMCID: PMC7425176.
24. Rao W, Wang S, Mahalingam R, Duleba M, Xie J, Gollar K, Niroula S, Qi Y, Neupane R, Liew A, Vincent M, Okuda K, **O'Neal WK**, Boucher RC, Dickey BF, Wechsler ME, Ibrahim O, Engelhardt JF, Crum CP, Mertens TCJ, Wang W, Jyothula SSK, Karmouty-Quintana H, Parekh KR, Metersky ML, McKeon FD, Xian W. 2020. Regenerative metaplastic clones in COPD lung drive inflammation and fibrosis. *Cell*. 181(4):848-864.e18. PMID: 32298651. PMCID: PMC7294989.
25. van Heusden C, Button B, Anderson WH, Ceppe A, Morton LC, **O'Neal WK**, Dang H, Alexis NE, Donaldson SH, Stephan H, Boucher RC, Lazarowski ER. 2020. Inhibition of ATP hydrolysis restores airway surface liquid production in cystic fibrosis airway epithelia. *Am J Physiol Lung Cell Mol Physiol*. 318(2): L356-L365. PMID: 31800264. PMCID: PMC7052677.
26. Zhang WZ, Oromendia C, Kikkers SA, Butler JJ, O'Beirne S, Kim K, **O'Neal WK**, Freeman CM, Christenson SA, Peters SP, Wells JM, Doerschuk C, Putcha N, Barjaktarevic I, Woodruff PG, Cooper CB, Bowler RP, Comellas AP, Criner GJ, Paine R 3rd, Hansel NN, Han MK, Crystal RG, Kaner RJ, Ballman KV, Curtis JL, Martinez FJ, Cloonan SM. 2020. Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. *Sci Rep*. 10(1):10562. PMID: 32601308; PMCID: PMC7324559.
27. Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Paine Iii R, Bhatt SP, Bhakta NR, Arjomandi M, Kaner RJ, Pirozzi CS, Curtis JL, **O'Neal WK**, Woodruff PG, Han MK, Martinez FJ, Hansel N, Wells JM, Ortega VE, Hoffman EA, Doerschuk CM, Kim V, Dransfield MT, Drummond MB, Bowler R, Criner G, Christenson SA, Ronish B, Peters SP, Krishnan JA, Tashkin DP, Cooper CB; NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS). 2019. Clinical significance of bronchodilator responsiveness evaluated by forced vital capacity in COPD: SPIROMICS cohort analysis. *Int J Chron Obstruct Pulmon Dis*. 14:2927-2938. PMID: 31908441. PMCID: PMC6930016.
28. Chen G, Ribeiro CMP, Sun L, Okuda K, Kato T, Gilmore RC, Martino MB, Dang H, Abzhanova A, Lin JM, Hull-Ryde EA, Volmer AS, Randell SH, Livraghi-Butrico A, Deng Y, Scherer PE, Stripp BR, **O'Neal WK**, Boucher RC. 2019. XBP1S regulates MUC5B in a promoter variant-dependent pathway in IPF airway epithelia. *Am J Respir Crit Care Med*. 200(2):220-234. PMID: 30973754; PMCID: PMC6635783.
29. Chen G, Sun L, Kato T, Okuda K, Martino MB, Abzhanova A, Lin JM, Gilmore RC, Batson BD, O'Neal YK, Volmer AS, Dang H, Deng Y, Randell SH, Button B, Livraghi-Butrico A, Kesimer M, Ribeiro CM, **O'Neal WK**, Boucher RC. 2019. IL-1 $\beta$  dominates the promucin secretory cytokine profile in cystic fibrosis. *J Clin Invest*. 129(10):4433-4450. PMID: 31524632. PMCID: PMC6763234.
30. Christenson SA, van den Berge M, Faiz A, Inkamp K, Bhakta N, Bonser LR, Zlock LT, Barjaktarevic IZ, Barr RG, Bleecker ER, Boucher RC, Bowler RP, Comellas AP, Curtis JL, Han MK, Hansel NN, Hiemstra PS, Kaner RJ, Krishnanm JA, Martinez FJ, **O'Neal WK**, Paine R 3rd, Timens W, Wells JM, Spira A, Erle

- DJ, Woodruff PG. 2019. An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. *J Clin Invest*. 129(1):169-181. PMID: 30383540; PMCID: PMC6307967.
31. Garudadri S, Woodruff PG, Han MK, Curtis JL, Barr RG, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G, Dransfield MT, Hansel NN, Paine R 3rd, Krishnan JA, Peters SP, Hastie AT, Martinez FJ, **O'Neal WK**, Couper DJ, Alexis NE, Christenson SA. 2019. Systemic markers of inflammation in smokers with symptoms despite preserved spirometry in SPIROMICS. *Chest*. 155(5):908-917. PMID: 30684474; PMCID: PMC6533449.
  32. Gong J, Wang F, Xiao B, Panjwani N, Lin F, Keenan K, Avolio J, Esmaeili M, Zhang L, He G, Soave D, Mastromatteo S, Baskurt Z, Kim S, **O'Neal WK**, Polineni D, Blackman SM, Corvol H, Cutting GR, Drumm M, Knowles MR, Rommens JM, Sun L, Strug LJ. 2019. Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. *PLoS Genet*. 15(2):e1008007. PMID: 30807572; PMCID: PMC6407791.
  33. Halper-Stromberg E, Gillenwater L, Cruickshank-Quinn C, **O'Neal WK**, Reisdorph N, Petrache I, Zhuang Y, Labaki WW, Curtis JL, Wells J, Rennard S, Pratte KA, Woodruff P, Stringer KA, Kechris K, Bowler RP. 2019. Bronchoalveolar Lavage Fluid from COPD Patients Reveals More Compounds Associated with Disease than Matched Plasma. *Metabolites*. 9(8). PMID: 31349744; PMCID: PMC6724137.
  34. Hobbs BD, Putman RK, Araki T, Nishino M, Gudmundsson G, Gudnason V, Eiriksdottir G, Zilhao Nogueira NR, Dupuis J, Xu H, O'Connor GT, Manichaikul A, Nguyen J, Podolanczuk AJ, Madahar P, Rotter JI, Lederer DJ, Barr RG, Rich SS, Ampleford EJ, Ortega VE, Peters SP, **O'Neal WK**, Newell JD Jr, Bleecker ER, Meyers DA, Allen RJ, Oldham JM, Ma SF, Noth I, Jenkins RG, Maher TM, Hubbard RB, Wain LV, Fingerlin TE, Schwartz DA, Washko GR, Rosas IO, Silverman EK, Hatabu H, Cho MH, Hunninghake GM; COPDGene Investigators, ECLIPSE Investigators, SPIROMICS Research Group, and UK ILD Consortium. 2019. Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 200(11):1402-1413. PMID: 31339356. PMCID: PMC6884045.
  35. Labaki WW, Gu T, Murray S, Curtis JL, Yeomans L, Bowler RP, Barr RG, Comellas AP, Hansel NN, Cooper CB, Barjaktarevic I, Kanner RE, Paine R 3rd, McDonald MN, Krishnan JA, Peters SP, Woodruff PG, **O'Neal WK**, Diao W, He B, Martinez FJ, Standiford TJ, Stringer KA, Han MK. 2019. Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. *Sci Rep*. 9(1):11367. PMID: 31388056; PMCID: PMC6684630.
  36. Okuda K, Chen G, Subramani DB, Wolf M, Gilmore RC, Kato T, Radicioni G, Kesimer M, Chua M, Livraghi-Burtrico A, Ehre C, Doerschuk CM, Randell SH, Matsui H, Nagase T, **O'Neal WK**, Boucher RC. 2019. Localization of secretory mucins MUC5AC and MUC5B in normal human airways. *Am J Respir Crit Care Med*. 199(6):715-727. PMID: 30352166; PMCID: PMC6423099.
  37. Ash SY, Harmouche R, Putman RK, Ross JC, Martinez FJ, Choi AM, Bowler RP, Regan EA, Curtis JL, Han MK, Boucher RC, **O'Neal WK**, Hatabu H, Lynch DA, Rosas IO, Hunninghake GM, San Jose Estepar R, Washko GR; COPDGene Investigators. 2018. Association between acute respiratory disease events and the MUC5B promoter polymorphism in smokers. *Thorax*. 73(11):1071-1074. PMID: 29440587; PMCID: PMC6089672.
  38. Burkes RM, Gassett AJ, Ceppe AS, Anderson W, **O'Neal WK**, Woodruff PG, Krishnan JA, Barr RG, Han MK, Martinez FJ, Comellas AP, Lambert AA, Kaufman JD, Dransfield MT, Wells JM, Kanner RE, Paine R 3rd, Bleecker ER, Paulin LM, Hansel NN, Drummond MB; SPIROMICS Investigators. 2018. Rural residence and COPD exacerbations: analysis of the SPIROMICS Cohort. *Ann Am Thorac Soc*. [Epub ahead of print]. PMID: 29584453; PMCID: PMC6207115.
  39. Chen G, Volmer AS, Wilkinson KJ, Deng Y, Jones LC, Yu D, Bustamante-Marin XM, Burns KA, Grubb BR, **O'Neal WK**, Livraghi-Butrico A, Boucher RC. 2018. Role of Spdef in the regulation of Muc5b expression in the airways of naïve and muco-obstructed mice. *Am J Respir Cell Mol Biol*. 59(3):383-396. PMID: 29579396; PMCID: PMC6189647.
  40. Kesimer M, Smith BM, Ceppe A, Ford AA, Anderson WH, Barr RG, **O'Neal WK**, Boucher RC; SPIROMICS Investigative Group. 2018. Mucin concentrations and peripheral airway obstruction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 198(11):1453-1456. PMID: 30130124; PMCID: PMC6290944.

41. Livraghi-Butrico A, Wilkinson KJ, Volmer AS, Gilmore RC, Rogers TD, Caldwell RA, Burns KA, Esther CR Jr, Mall MA, Boucher RC, **O'Neal WK**, Grubb BR. 2018. Lung disease phenotypes caused by over-expression of combinations of alpha, beta, and gamma subunits of the epithelial sodium channel in mouse airways. *Am J Physiol Lung Cell Mol Physiol*. ajplung.00382.2017. 314(2):L318-L331. PMID: 29074490; PMCID: PMC5866504.
42. Martinez CH, Li SX, Hirzel AJ, Stolberg VR, Alexis NE, Barr RG, Bleecker ER, Carretta EE, Christenson SA, Cooper CB, Couper DJ, Doerschuk CM, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kaner RJ, Martinez FJ, Meyers DA, **O'Neal WK**, Paine R 3rd, Putcha N, Rennard SI, Woodruff PG, Zeidler M, Curtis JL, Freeman CM; SPIROMICS Investigators. 2018. Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort. *J Allergy Clin Immunol*. 141(1):429-432. PMID: 28916185; PMCID: PMC5758424.
43. Morris MA, Jacobson SR, Kinney GL, Tashkin DP, Woodruff PG, Hoffman EA, Kanner RE, Cooper CB, Drummond MB, Barr RG, Oelsner EC, Make BJ, Han MK, Hansel NN, **O'Neal WK**, Bowler RP. 2018. Marijuana use associations with pulmonary symptoms and function in tobacco smokers enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). *Chronic Obstr Pulm Dis*. 5(1):46-56. PMID: 29629404; PMCID: PMC5870739.
44. Polineni D, Dang H, Jones L, Gallins P, Pace R, Stonebraker J, Commander L, Krenicky J, Zhou Y, Corvol H, Cutting G, Drumm M, Strug L, Boyle M, Durie P, Chmiel J, Zou F, Wright F, **O'Neal W**, Knowles M. 2018. Airway mucosal host defense is key to genomic regulation of cystic fibrosis lung disease severity. *Am J Respir Crit Care Med*. 197(1):79-93. PMID: 28853905; PMCID: PMC5765386.
45. Putcha N, Fawzy A, Paul GG, Lambert AA, Psoter KJ, Sidhaye VK, Woo J, Wells JM, Labaki WW, Doerschuk CM, Kanner RE, Han MK, Martinez C, Paulin LM, Martinez FJ, Wise RA, **O'Neal WK**, Barr RG, Hansel NN; SPIROMICS investigators. 2018. Anemia and adverse outcomes in a chronic obstructive pulmonary disease population with a high burden of comorbidities. An analysis from SPIROMICS. *Ann Am Thorac Soc*. 15(6):710-717. PMID: 30726108; PMCID: PMC6207135.
46. Putcha N, Paul GG, Azar A, Wise RA, **O'Neal WK**, Dransfield MT, Woodruff PG, Curtis JL, Comellas AP, Drummond MB, Lambert AA, Paulin LM, Fawzy A, Kanner RE, Paine R 3rd, Han MK, Martinez FJ, Bowler RP, Barr RG, Hansel NN; SPIROMICS investigators. 2018. Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. *PLoS One*. 13(4):e0194924. PMID: 29649230; PMCID: PMC5896903.
47. Rowson-Hodel AR, Wald JH, Hatakeyama J, **O'Neal WK**, Stonebraker JR, VanderVorst K, Saldana MJ, Borowsky AD, Sweeney C, Carraway KL Rd. 2018. Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. *Oncogene*. 37(2):197-207. PMID: 28892049; PMCID: PMC5930013.
48. Saini Y, Lewis BW, Yu D, Dang H, Livraghi-Butrico A, Del Piero F, **O'Neal WK**, Boucher RC. 2018. Effect of LysM+ macrophage depletion on lung pathology in mice with chronic bronchitis. *Physiol Rep*. 6(8):e13677. PMID: 29667749; PMCID: PMC5904692.
49. Anderson WH, Ha JW, Couper DJ, **O'Neal WK**, Barr RG, Bleecker ER, Carretta EE, Cooper CB, Doerschuk CM, Drummond MB, Han MK, Hansel NN, Kim V, Kleerup EC, Martinez FJ, Rennard SI, Tashkin D, Woodruff PG, Paine R 3rd, Curtis JL, Kanner RE; SPIROMICS Research Group. 2017. Variability in objective and subjective measures affects baseline values in studies of patients with COPD. *PLoS One*. 12(9):e0184606. PMID: 28934249; PMCID: PMC5608200.
50. Bowler RP, Hansel NN, Jacobson S, Graham Barr R, Make BJ, Han MK, **O'Neal WK**, Oelsner EC, Casaburi R, Barjaktarevic I, Cooper C, Foreman M, Wise RA, DeMeo DL, Silverman EK, Bailey W, Harrington KF, Woodruff PG, Drummond MB; for COPDGene and SPIROMICS Investigators. 2017. Electronic cigarette use in US adults at risk for or with COPD: analysis from two observational cohorts. *J Gen Intern Med*. 32(12):1315-1322. PMID: 28884423; PMCID: PMC5698219.
51. Choi S, Haghghi B, Choi J, Hoffman EA, Comellas AP, Newell JD, Wenzel SE, Castro M, Fain SB, Jarjour NN, Schiebler ML, Barr RG, Han MK, Bleecker ER, Cooper CB, Couper D, Hansel N, Kanner RE, Kazeroni EA, Kleerup EAC, Martinez FJ, **O'Neal WK**, Woodruff PG, Lin CL. 2017. Differentiation of quantitative CT imaging phenotypes in asthma versus COPD. *BMJ Open Respir Res*. 4(1):e000252. PMID: 29435345; PMCID: PMC5687530.

52. Donoghue LJ\*, Livraghi-Butrico A\*, McFadden KM, Thomas JM, Chen G, Grubb BR, **O'Neal WK**, Boucher RC, Kelada SNP. 2017. Identification of trans protein QTL for secreted airway mucins in mice and a causal role for Bpifb1. *Genetics*. 207(2):801-12. PMID: 28851744; PMCID: PMC5629340.
53. Han MK, Quibrera PM, Carretta EE, Barr RG, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL, Criner G, Dransfield MT, Hansel NN, Hoffman EA, Kanner RE, Krishnan JA, Martinez CH, Pirozzi CB, **O'Neal WK**, Rennard S, Tashkin DP, Wedzicha JA, Woodruff P, Paine R 3rd, Martinez FJ; SPIROMICS investigators. 2017. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. *Lancet Respir Med*. 5(8):619-26. PMID: 28668356; PMCID: PMC555885.
54. Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, Barr RG, Carretta EE, Couper DJ, Cooper CB, Hoffman EA, Kanner RE, Kleeerup E, **O'Neal WK**, Paine R 3rd, Peters SP, Alexis NE, Woodruff PG, Han MK, Meyers DA, Bleecker ER; SPIROMICS investigators. 2017. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. *Lancet Respir Med*. 2017 Dec;5(12):956-967. PMID: 29146301; PMCID: PMC5849066.
55. Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, Davis WC, Doerschuk CM, Alexis NE, Anderson WH, Henderson AG, Barr G, Bleecker ER, Christenson SA, Cooper CB, Han MLK, Hansel NN, Hastie AT, Hoffman EA, Kanner RE, Martinez F, Paine R, Woodruff PG, **O'Neal WK**, Boucher RC. 2017. Airway mucin concentration as a marker of chronic bronchitis. *N Engl J Med*. 377(10):911-22. PMID: 28877023; PMCID: PMC5706541.
56. Livraghi-Butrico A, Grubb BR, Wilkinson K, Volmer AS, Burns KA, Evans C, **O'Neal WK\***, Boucher RC\*. 2017. Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. *Mucosal Immunol*. 10(2):395-407. PMID: 27435107; PMCID: PMC5250616. **\*co-senior authors; equal contribution. Correction:** *Mucosal Immunol*. 2017;10(3):829. PMID: 28435155.
57. Nishida K, Brune KA, Putcha N, Mandke P, **O'Neal WK**, Shade D, Srivastava V, Wang M, Lam H, An SS, Drummond MB, Hansel NN, Robinson DN, Sidhaye VK. 2017. Cigarette smoke disrupts monolayer integrity by altering epithelial cell-cell adhesion and cortical tension. *Am J Physiol Lung Cell Mol Physiol*. 313(3):L581-91. PMID: 28642260; PMCID: PMC5625260.
58. **O'Neal WK**. 2017. Lung cell-specific Cre deleter mouse strains: going back to move forward. *Am J Respir Cell Mol Biol*. 57(2):149-50. PMID: 28762768.
59. Dang H, Gallins PJ, Pace RG, Guo XL, Stonebraker JR, Corvol H, Cutting GR, Drumm ML, Strug LJ, Knowles MR, **O'Neal WK**. 2016. Novel variation at chr11p13 associated with cystic fibrosis lung disease severity. *Hum Genome Var*. Jul 7;3:16020. PMID: 27408752; PMCID: PMC4935763. **Corrigendum:** *Hum Genome Var*. 2017;4:17016. PMID: 28674633; PMCID: PMC5477836.
60. Keene JD, Jacobson S, Kechris K, Kinney GL, Foreman MG, Doerschuk CM, Make BJ, Curtis JL, Rennard SI, Barr RG, Bleecker ER, Kanner RE, Kleeerup EC, Hansel NN, Woodruff PG, Han MK, Paine III R, Martinez FJ, Bowler RP\*, **O'Neal WK\***; for COPDGene and SPIROMICS Investigators. 2016. Biomarkers predictive of exacerbations in the SPIROMICS and COPDGene Cohorts. *Am J Respir Crit Care Med*. 195(4):473-81. PMID: 27579823; PMCID: PMC5378424. **\*co-senior authors; equal contribution**
61. Saini Y, Wilkinson KJ, Terrell KA, Burns KA, Livraghi-Butrico A, Doerschuk CM, **O'Neal WK**, Boucher RC. 2016. Neonatal pulmonary macrophage depletion coupled to defective mucus clearance increases susceptibility to pneumonia and alters pulmonary immune responses. *Am J Respir Cell Mol Biol*. 54(2):210-21. PMID: 26121027; PMCID: PMC4821038.
62. Sun W, Kechris K, Jacobson S, Drummond MB, Hawkins GA, Yang J, Chen TH, Quibrera PM, Anderson W, Barr RG, Basta PV, Bleecker ER, Beaty T, Casaburi R, Castaldi P, Cho MH, Comellas A, Crapo JD, Criner G, Demeo D, Christenson SA, Couper DJ, Curtis JL, Doerschuk CM, Freeman CM, Gouskova NA, Han MK, Hanania NA, Hansel NN, Hersh CP, Hoffman EA, Kaner RJ, Kanner RE, Kleeerup EC, Lutz S, Martinez FJ, Meyers DA, Peters SP, Regan EA, Rennard SI, Scholand MB, Silverman EK, Woodruff PG, **O'Neal WK\***, Bowler RP\*; SPIROMICS Research Group; COPDGene Investigators. 2016. Common

- genetic polymorphisms influence blood biomarker measurements in COPD. *PLoS Genetics*. 12(8):e1006011. PMID: 27532455; PMCID: PMC4988780. **\*co-senior/corresponding authors**
63. Yu D, Davis RM, Aita M, Burns KA, Clapp PW, Gilmore RC, Chua M, **O'Neal WK**, Schlegel R, Randell SH, C Boucher R. 2016. Characterization of rat meibomian gland ion and fluid transport. *Invest Ophthalmol Vis Sci*. 57(4):2328-43. PMID: 27127933; PMCID: PMC4855829.
  64. Corvol H, Blackman SM, Boëlle PY, Gallins PJ, Pace RG, Stonebraker JR, Accurso FJ, Clement A, Collaco JM, Dang H, Dang AT, Franca A, Gong J, Guillot L, Keenan K, Li W, Lin F, Patrone MV, Raraigh KS, Sun L, Zhou YH, **O'Neal WK**, Sontag MK, Levy H, Durie PR, Rommens JM, Drumm ML, Wright FA, Strug LJ, Cutting GR, Knowles MR. 2015. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. *Nat Commun*. 6:8382. PMID: 26417704; PMCID: PMC4589222.
  65. Freeman CM, Crudgington S, Stolberg VR, Brown JP, Sonstein J, Alexis NE, Doerschuk CM, Basta PV, Carretta EE, Couper DJ, Hastie AT, Kaner RJ, **O'Neal WK**, Paine R 3rd, Rennard SI, Shimbo D, Woodruff PG, Zeidler M, Curtis JL. 2015. Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). *J Transl Med*. 13:19. PMID: 25622723; PMCID: PMC4314767.
  66. Lubamba BA, Jones LC, **O'Neal WK**, Boucher RC, Ribeiro CM. 2015. X-box-binding protein 1 and innate immune responses of human cystic fibrosis alveolar macrophages. 2015. *Am J Respir Crit Care Med*. 192(12):1449-61. PMID: 26331676; PMCID: PMC4731720.
  67. **O'Neal WK**, Gallins P, Pace RG, Dang H, Wolf WE, Jones LC, Guo X, Zhou YH, Madar V, Huang J, Liang L, Moffatt MF, Cutting GR, Drumm ML, Rommens JM, Strug LJ, Sun W, Stonebraker JR, Wright FA, Knowles MR. 2015. Gene expression in transformed lymphocytes reveals variation in endomembrane and HLA pathways modifying cystic fibrosis pulmonary phenotypes. *Am J Hum Genet*. 96(2):318-28. PMID: 25640674; PMCID: PMC4320265.
  68. Bove PF, Dang H, Cheluvharaju C, Jones LC, Liu X, **O'Neal WK**, Randell SH, Schlegel R, Boucher RC. 2014. Breaking the in vitro alveolar type II cell proliferation barrier while retaining ion transport properties. *Am J Respir Cell Mol Biol*. 50(4):767-76. PMID: 24191670; PMCID: PMC4068919.
  69. Carolan BJ, Hughes G, Morrow J, Hersh CP, **O'Neal WK**, Rennard S, Pillai SG, Belloni P, Cockayne DA, Comellas AP, Han M, Zemans RL, Kechris K, Bowler RP. 2014. The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. *Respir Res*. 15:127. PMID: 25306249; PMCID: PMC4198701.
  70. Fossum SL, Mutolo MJ, Yang R, Dang H, **O'Neal WK**, Knowles MR, Leir SH, Harris A. 2014. Ets homologous factor regulates pathways controlling response to injury in airway epithelial cells. *Nucleic Acids Res*. 42(22):13588-98. PMID: 25414352; PMCID: PMC4267623.
  71. Guo X, Pace RG, Stonebraker JR, **O'Neal WK**, Knowles MR. 2014. Meconium ileus in cystic fibrosis is not linked to central repetitive region length variation in MUC1, MUC2, and MUC5AC. *J Cyst Fibros*. 13(6):613-6. PMID: 24920497; PMCID: PMC4253052.
  72. Guo X, Zheng S, Dang H, Pace RG, Stonebraker JR, Jones CD, Boellmann F, Yuan G, Haridass P, Fedrigo O, Corcoran DL, Seibold MA, Ranade SS, Knowles MR, **O'Neal WK\***, Voynow JA\*. 2014. Genome reference and sequence variation in the large central repetitive central exon of human MUC5AC. *Am J Respir Cell Mol Biol*. 50:223-32. PMID: 24010879; PMCID: PMC3930937. **\*Equal Co-Senior authors.**
  73. **O'Neal WK**, Anderson W, Basta PV, Carretta EE, Doerschuk CM, Barr RG, Bleecker ER, Christenson SA, Curtis JL, Han MK, Hansel NN, Kanner RE, Kleerup EC, Martinez FJ, Miller BE, Peters SP, Rennard SI, Scholand MB, Tal-Singer R, Woodruff PG, Couper DJ, Davis S. 2014. Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. *J Trans Med*. 12:9. PMID: 24397870; PMCID: PMC3928911.
  74. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK, Song AS, Petrova YM, Tuvim MJ, Adachi R, Romo I, Bordt AS, Bowden MG, Sisson JH, Woodruff PG, Thornton DJ, Rousseau K, De la Garza MM, Moghaddam SJ, Karmouty-Quintana H,

- Blackburn MR, Drouin SM, Davis CW, Terrell KA, Grubb BR, **O'Neal WK**, Flores SC, Cota-Gomez A, Lozupone CA, Donnelly JM, Watson AM, Hennessy CE, Keith RC, Yang IV, Barthel L, Henson PM, Janssen WJ, Schwartz DA, Boucher RC, Dickey BF, Evans CM. 2014. Muc5b is required for airway defence. *Nature*. 505:412-6. PMID: 24317696; PMCID: PMC4001806.
75. Saini Y, Dang H, Livraghi-Butrico A, Kelly EJ, Jones LC, **O'Neal WK**, Boucher RC. 2014. Gene expression in whole lung and pulmonary macrophages reflects the dynamic pathology associated with airway surface dehydration. *BMC Genomics*. 15:726. PMID: 25204199; PMCID: PMC4247008.
76. Livraghi-Butrico A, Kelly EJ, Wilkinson KJ, Rogers TD, Gilmore RC, Harkema JR, Randell SH, Boucher RC, **O'Neal WK**, Grubb BR. 2013. Loss of CFTR function exacerbates the phenotype of Na(+) hyperabsorption in murine airways. *Am J Physiol Lung Cell Mol Physiol*. 304:L469-480. PMID: 23377346; PMCID: PMC3627939.
77. Martino MB, Jones L, Brighton B, Ehre C, Abdulah L, Davis CW, Ron D, **O'Neal WK**, Ribeiro CM. 2013. The ER stress transducer IRE1 $\beta$  is required for airway epithelial mucin production. *Mucosal Immunol*. 6:639-54. PMID: 23168839; PMCID: PMC4031691.
78. Sesma JI, Kreda SM, Okada SF, van Heusden C, Moussa L, Jones LC, **O'Neal WK**, Togawa N, Hiasa M, Moriyama Y, Lazarowski ER. 2013. Vesicular nucleotide transporter regulates the nucleotide content in airway epithelial mucin granules. *Am J Physiol Cell Physiol*. 304:C976-84. PMID: 23467297; PMCID: PMC3651637.
79. Ehre C, Worthington EN, Liesman RM, Grubb BR, Barbier D, **O'Neal WK**, Sallenave JM, Pickles RJ, Boucher RC. 2012. Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs. *Proc Natl Acad Sci U S A*. 109:16528-33. PMID: 23012413; PMCID: PMC3478656.
80. Livraghi-Butrico A, Kelly EJ, Klem ER, Dang H, Wolfgang MC, Boucher RC, Randell SH, **O'Neal WK**. 2012. Mucus clearance, MyD88-dependent and MyD88-independent immunity modulate lung susceptibility to spontaneous bacterial infection and inflammation. *Mucosal Immunol*. 5:397-408. PMID: 22419116; PMCID: PMC3377774.
81. Livraghi-Butrico A, Grubb BR, Kelly EJ, Wilkinson KJ, Yang H, Geiser M, Randell SH, Boucher RC, **O'Neal WK**. 2012. Genetically determined heterogeneity of lung disease in a mouse model of airway mucus obstruction. *Physiol Genomics*. 44:470-84. PMID: 22395316; PMCID: PMC3339860.
82. Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, Lin F, Dorfman R, Busson, PF, Parekh RV, Zelenika D, Blackman SM, Corey M, Doshi VK, Henderson L, Naughton KM, **O'Neal WK**, Pace RG, Stonebraker JR, Wood SD, Wright FA, Zielenski J, Clement A, Drumm ML, Boelle PY, Cutting GR, Knowles MR, Durie PR, Strug LJ. 2012. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. *Nat Genet*. 44a:562-9. PMID: 22466613; PMCID: PMC3371103.
83. Grubb BR, **O'Neal WK**, Ostrowski LE, Kreda SM, Button B, Boucher RC. 2011. Transgenic hCFTR expression fails to correct  $\beta$ ENaC mouse lung disease. *Am J Physiol Lung Cell Mol Physiol*. 302:L238-47. PMID: 22003093; PMCID: PMC3349361.
84. Guo X, Pace RG, Stonebraker JR, Commander CW, Dang AT, Drumm ML, Harris A, Zou F, Swallow DM, Wright FA, Knowles MR\*, **O'Neal WK\***. 2011. Mucin variable number tandem repeat polymorphisms and severity of cystic fibrosis lung disease: significant association with MUC5AC. *PLoS One*. 6:e25452. PMID: 21998660; PMCID: PMC3188583. \* **Co-Senior authors**.
85. Jones LC, Moussa L, Fulcher LM, Zhu Y, Hudson EJ, **O'Neal WK**, Randell SH, Lazarowski ER, Boucher RC, Kreda SM. 2011. VAMP8 is a vesicle SNARE that regulates mucin secretion in airway goblet cells. *J Physiol*. 590:545-62. PMID: 22144578; PMCID: PMC3379700.
86. Nguyen Y, Procaro MC, Ashley SL, **O'Neal WK**, Pickles RJ, Weinberg JB. 2011. Limited effects of Muc1 deficiency on mouse adenovirus type 1 respiratory infection. *Virus Res*. 160:351359. PMID: 21816184; PMCID: PMC3163747.
87. Seminario-Vidal L, Okada SF, Sesma JI, Kreda SM, van Heusden CA, Zhu Y, Jones LC, **O'Neal WK**, Penuela S, Laird DW, Boucher RC, Lazarowski ER. 2011. Rho signaling regulates pannexin 1-mediated ATP release from airway epithelia. *J Biol Chem*. 286:26277-86. PMID: 21606493; PMCID: PMC3143590.
88. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM, Corey M, Dorfman R, Goddard K, Green D, Kent JW Jr, Lange EM, Lee S, Li W,

- Luo J, Mayhew GM, Naughton KM, Pace RG, Pare P, Rommens JM, Sandford A, Stonebraker JR, Sun W, Taylor C, Vanscoy LL, Zou F, Blangero J, Zielenski J, **O'Neal WK**, Drumm ML, Durie PR, Knowles MR, Cutting GR. 2011. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. *Nat Genet.* 43:539-46. PMID: 21602797; PMCID: PMC3296486.
89. Bove P, Grubb BR, Okada SF, Ribeiro CM, Rogers TD, Randell SH, **O'Neal WK**, Boucher RC. 2010. Human alveolar type II cells secrete and absorb liquid in response to local nucleotide signaling. *J Biol Chem.* 285:34939-49. PMID: 20801871; PMCID: PMC2966108.
90. Cholon DM, **O'Neal WK**, Randell SH, Riordan JR, Gentsch M. 2010. Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures. *Am J Physiol Lung Cell Mol Physiol.* 298:L304-14. PMID: 20008117; PMCID: PMC2838667.
91. Greenberg J, Deshmukh R, Huang L, Mostafa J, LaVange L, Carretta E, **O'Neal W**. 2010. The COPD Ontology and toward empowering clinical scientists as ontology engineers. *J Library Metadata.* 10:173-87.
92. Kreda SM, Seminario-Vidal L, van Heusden CA, **O'Neal W**, Jones L, Boucher RC, Lazarowski ER. 2010. Receptor-promoted exocytosis of airway epithelial mucin granules containing a spectrum of adenine nucleotides. *J Physiol.* 588:2255-67. PMID: 20421285; PMCID: PMC2911224.
93. Mall MA, Button B, Johannesson B, Zhou Z, Livraghi A, Caldwell RA, Schubert SC, Schultz C, **O'Neal WK**, Pradervand S, Hummler E, Rossier BC, Brubb BR, Boucher RC. 2010. Airway surface liquid volume regulation determines different airway phenotypes in Liddle compared with beta ENaC-overexpressing mice. *J Biol Chem.* 285:26945-55. PMID: 20566636; PMCID: PMC2930694.
94. Ostrowski LE, Yin W, Rogers TD, Busalacchi KB, Chua M, **O'Neal WK**, Grubb BR. 2010. Conditional deletion of Dnaic1 in a murine model of primary ciliary dyskinesia causes chronic rhinosinusitis. *Am J Respir Cell Mol Biol.* 43:55-63. PMID: 19675306; PMCID: PMC2911571.
95. Kesimer M, Scull M, Brighton B, Demaria G, Burns K, **O'Neal W**, Pickles RJ, Sheehan JK. 2009. Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. *FASEB J.* 23:1858-68. PMID: 19190083; PMCID: PMC2698655.
96. Livraghi A, Grubb BR, Hudson EJ, Wilkinson KJ, Sheehan JK, Mall MA, **O'Neal WK**, Boucher RC, Randell SH. 2009. Airway and lung pathology due to mucosal surface dehydration in {beta}-epithelial Na<sup>+</sup> channel overexpressing mice: role of TNF- $\alpha$  and IL-4R $\alpha$  signaling, influence of neonatal development, and limited efficacy of glucocorticoid treatment. *J Immunol.* 182:4357-67. PMID: 19299736; PMCID: PMC2659461.
97. Martino ME, Olsen JC, Fulcher NB, Wolfgang MC, **O'Neal WK**, Ribeiro CM. 2009. Airway epithelial inflammation-induced endoplasmic reticulum Ca<sup>2+</sup> store expansion is mediated by X-box binding protein-1. *J Biol Chem.* 284:14904-13. PMID: 19321437; PMCID: PMC2685672.
98. Ribeiro CMP, Hurd H, Wu Y, Martino MEB, Jones L, Brighton B, Boucher RC, **O'Neal WK**. 2009. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. *PLoS ONE.* 4:e5806. PMID: 19503797; PMCID: PMC2688381.
99. Rock JR, **O'Neal WK**, Gabriel SE, Randell SH, Harfe BD, Boucher RC, Grubb BR. 2009. Transmembrane protein 16a (Tmem16a) Is A Ca<sup>++</sup> regulated Cl<sup>-</sup> secretory channel In mouse airways. *J Biol Chem.* 284:14875-80. PMID: 19363029; PMCID: PMC2685669.
100. Seminario-Vidal L, Kreda S, Jones L, **O'Neal W**, Trejo J, Boucher RC, Lazarowski ER. 2009. Thrombin promotes release of ATP from lung epithelial cells through coordinated activation of Rho- and Ca<sup>2+</sup>-dependent signaling pathways. *J Biol Chem.* 284:20638-48. PMID: 19439413; PMCID: PMC2742828.
101. Sesma JI, Esther CR Jr, Kreda SM, Jones L, **O'Neal W**, Nishihara S, Nicholas RA, Lazarowski ER. 2009. ER/golgi nucleotide sugar transporters contribute to the cellular release of UDP-sugar signaling molecules. *J Biol Chem.* 284:12572-83. PMID: 19276090; PMCID: PMC2673323.
102. Mall MA, Harkema J, Trojanek JB, Treis D, Schubert S, Zhou Z, Hudson EJ, Kreda S, Livraghi A, **O'Neal WK**, Boucher RC. 2008. Development of chronic bronchitis and emphysema in  $\beta$ ENaC overexpressing mice. *Am J Respir Crit Care Med.* 177:730-42. PMID: 18079494; PMCID: PMC2277210.

103. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy J, **O'Neal W**, Sorscher EJ, Abraham E, Blalock JE. 2008. Potential role of high mobility group box 1 in cystic fibrosis airway disease. *Am J Respir Crit Care Med.* 178:822-31. PMID: 18658107; PMCID: PMC2566793.
104. Kreda SM, Okada SF, van Heusden CA, **O'Neal W**, Gabriel S, Abdullah L, Davis CW, Boucher RC, Lazarowski ER. 2007. Coordinated release of nucleotides and mucin from human airway epithelial Calu-3 cells. *J Physiol.* 584:245-59. PMID: 17656429; PMCID: PMC2277076.
105. Ostrowski, LE, Yin W, Diggs PS, Rogers TD, **O'Neal, WK**, and Grubb, BR. 2007. Expression of CFTR from a ciliated cell-specific promoter is ineffective at correcting nasal potential difference in CF mice. *Gene Ther.* 14:1492-1501. PMID: 17637798.
106. Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, Alb JG, Magnuson TR, **O'Neal W**, Milgram SL. 2006. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of yap65. *Mol Cell Biol.* 26:77-87. PMID: 16354681; PMCID: PMC1317614.
107. Barnes AP, Livera G, Huang P, Sun C, **O'Neal WK**, Conti M, Stutts MJ, Milgram SL. 2005. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. *J Biol Chem.* 280:7997-8003. PMID: 15611099.
108. Neuringer IP, Sloan J, Budd S, Chalermkulrat W, Park RCW, Stonebraker JR, **O'Neal WK**, Aris RM, Randell, SH. 2005. Calcineurin inhibitor effects on growth and phenotype of human airway epithelial cells in vitro. *Am J Transplantation.* 11:2660-70. PMID: 16212625.
109. Ribeiro CM, Paradiso AM, Schwab U, Perez-Vilar J, Jones L, **O'Neal WK**, Boucher RC. 2005. Chronic airway infection/inflammation induces a Ca<sup>2+</sup> independent hyperinflammatory response in human cystic fibrosis airway epithelia. *J Biol Chem.* 280:17798-806. PMID: 15746099.
110. Mall M, Grubb BR, Harkema JR, **O'Neal WK**, Boucher RC. 2004. Increased airway epithelial Na<sup>+</sup> absorption produces cystic fibrosis-like lung disease in mice. *Nat Med.*10:487-93. PMID: 15077107.
111. Okada SF, **O'Neal WK**, Huang P, Nicholas RA, Craigen WJ, Lazarowski ER, Boucher RC. 2004. A role of plasmalemmal voltage-dependent anion channel-1 (pI-VDAC-1) in ATP release and regulatory volume decrease in airway epithelial cells. *J Gen Physiol.*124:513-26. PMID: 15477379.
112. Stonebraker JR, Wagner D, Lefensty RW, Burns K, Gendler SJ, Bergelson JM, Boucher RC, **O'Neal WK**, Pickles RJ. 2004. Glycocalyx restricts adenoviral vector access to apical receptors expressed on respiratory epithelium in vitro and in vivo: role for tethered mucins as barriers to luminal infection. *J Virol.* 78: 13755-68. PMID: 15564484; PMCID: PMC533903.
113. Zariwala M\*, **O'Neal WK\***, Noone PG, Leigh MW, Knowles MR, Ostrowski LE. 2004. Investigation of the possible role of a novel gene, DPCD, in Primary Ciliary Dyskinesia. *Am J Respir Cell Mol Biol.* 30:428-34. PMID: 14630615. **\*authors contributed equally to manuscript.**
114. Coakley RD, Grubb BR, Paradiso AM, Gatzky JT, Johnson LG, Kreda SM, **O'Neal WK**, Boucher RC. 2003. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. *Proc Natl Acad Sci U S A.* 100:16083-8. PMID: 14668433; PMCID: PMC307696.
115. Ostrowski LE, Hutchins JR, Zakel K, **O'Neal WK**. 2003. Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter. *Mol Ther.* 8:637-45. PMID: 14529837.
116. Morral N, **O'Neal WK**, Rice K, Leland M, Piedra PA, Aguilar-Cordova E, Carey KD, Beaudet AL, Langston C. 2002. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. *Hum Gene Ther.* 13:143-54. PMID: 11779418.
117. Zhang YJ, **O'Neal WK**, Randell SH, Blackburn K, Moyer MB, Boucher RC, Ostrowski LE. 2002. Identification of dynein heavy chain 7 as an inner arm component of human cilia that is synthesized but not assembled in a case of primary ciliary dyskinesia. *J Biol Chem.* 17:17906-15. PMID: 11877439.
118. Lazarowski E, Rochelle LG, **O'Neal WK**, Ribeiro CP, Grubb BR, Harden TK, Boucher RC. 2001. Cloning and functional characterization of two murine uridine nucleotide receptors reveal a potential target for correcting ion transport deficiency in cystic fibrosis gallbladder. *J Pharm Exp Ther.* 297:43-9. PMID: 11259526.

119. **O'Neal WK**, Rose E, Velji R, Zhou H, Quinones J, Langston C, Rice K, Carey D, Beaudet AL. 2000. Multiple advantages of alpha-fetoprotein as a marker for in vivo gene transfer. *Mol Ther.* 6:640-8. PMID: 11124066.
120. **O'Neal WK**, Zhou H, Morral N, Langston C, Parks R, Graham F, Kochanek S, Beaudet AL. 2000. Toxicity associated with repeated administration of first-generation adenoviral vectors is not induced by a helper-dependent vector. *Mol Med.* 6:179-95. PMID: 10965494; PMCID: PMC1949942.
121. Morral N, **O'Neal WK**, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks R, Velji R, Quinones J, Aguilar-Cordova E, Wadsworth S, Graham F, Kochanek S, Langston C, Carey KD, Beaudet AL. 1999. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. *Proc Natl Acad Sci U S A.* 96:12816-21. PMID: 10536005; PMCID: PMC23112.
122. Morris AP, Ball JM, Zeng Q-Y, Scott JK, **O'Neal WK**, Estes MK. 1999. NSP4 elicits age-dependent diarrhea and Ca<sup>2+</sup> mediated I<sup>-</sup> efflux into intestinal crypts of CF mice. *Am J Physiol.* 40:G431-44. PMID: 10444458.
123. **O'Neal WK**, Zhou H, Morral N, Aguilar-Cordova E, Pestaner J, Langston C, Mull B, Wang Y, Beaudet AL, Lee B. 1998. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. *Hum Gene Ther.* 9:1587-98. PMID: 9694157.
124. Morral N, **O'Neal WK**, Zhou H, Langston C, Beaudet AL. 1997. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. *Hum Gene Ther.* 8:1275-86. PMID: 9215744.
125. Zhou H, **O'Neal WK**, Morral N, Beaudet AL. 1997. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. *J Virol.* 70:7030-8. PMID: 8794347.
126. Hasty P, **O'Neal WK**, Liu, K-Q, Morris AP, Bebok Z, Shumyatsky GB, Jilling T, Sorscher EJ, Bradley A, Beaudet AL. 1995. Severe phenotype in mice with termination mutation in Exon 2 of cystic fibrosis gene. *Somat Cell Mol Genet.* 21:177-87. PMID: 7482032.
127. **O'Neal WK**, Hasty EP, McCray PB Jr., Casey B, Rivera-Perez J, Welsh MJ, Beaudet AL, Bradley A. 1993. A severe phenotype in mice with a duplication of exon 3 in the cystic fibrosis gene. *Hum Mol Genet.* 2:1561-9. PMID: 7505691.
128. Yorifugi T, **Lemna (O'Neal) WK**, Ballard CF, Rosenbloom CL, Roxmahel R, Plavsic N, Tsui L-C, Beaudet, AL. 1991. Molecular cloning and sequence analysis of murine cDNA for the cystic fibrosis transmembrane conductance regulator. *Genomics.* 10:547-50. PMID: 1716243.
129. **Lemna (O'Neal) WK**, Feldman GL, Kerem B, Fernbach SD, Zevkovich EP, O'Brien WE, Riordan JR, Collins FS, Tsui, L-C, Beaudet, AL. 1990. Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. *New Engl J Med.* 322:291-6. PMID: 2296270.

**Published Abstracts (from newest to oldest):**

1. Lemaster WB, Quibrera PM, Couper D, Tashkin DP, Bleecker ER, Doerschuk CM, Ortega VE, Cooper CB, Han MK, Woodruff P, **O'Neal WK**, W. H. Anderson, Alexis NE, Curtis JL, Bowler RP, Barr R, Kaner J, Dransfield MT, Paine R, Kim V, Martinez FJ, Hastie AT, Barjaktarevic I. 2021. Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort. *Am J Respir Crit Care Med.* 203: A1245.
2. O'Beirne S, Salit J, Alexis NE, Arjomandi M, Barjaktarevic I, Basta P, Bowler RP, Christenson SA, Cloonan SM, Curtis JL, Doerschuk CM, Drummond MB, Hastie AT, Huang YJ, Kim V, **O'Neal WK**, Ortega VE, Postow L, Putcha N, Rennard SI, Wells JM, Woodruff P, Zhang WZ, Crystal RG, Kaner RJ. 2021. Secondhand Smoke Alters Alveolar Macrophage Gene Expression. *Am J Respir Crit Care Med.* 203:A2318.
3. Ortega VE, Paulin LM, Kaufman JD, Ampleford E, Woo H, Hawkins GA, Li X, Barjaktarevic I, Bhatt SP, Bowler RP, Barr RG, Cooper CB, Couper D, Curtis JL, Gassett AJ, Han MK, Kanner RE, Kim V, Martinez FJ, Moore WC, **O'Neal WK**, Paine R, Smith BP, Smith B, Woodruff P, Hoffman EA, Peters SP, Meyers

- DA, Bleecker ER, Hansel NN. 2021. Air Pollutant Exposure-by-Gene Interactions Associated with Emphysema, Lung Structure, and Lung Function in SPIROMICS. *Am J Respir Crit Care Med.* 203: A1095.
4. Chen G, Sun L, Esther CR, Wolfgang M, Kesimer M, Hill D, Ramsey KA, Button B, Quinney N, Gentzsch M, **O'Neal WK**, Freeman A, Robinson C, Bogdanovski K, Olivier KN, Boucher RC. 2020. Defective Epithelial Mucociliary Differentiation Leads to Mucin Hyperconcentration in the Autosomal Dominant Hyper Ige Syndrome (AD-HIES) Airways. *Am J Respir Crit Care Med.* 201: A6395.
  5. Eastman AC, Pace RG, Dang H, Aksit MA, Vecchio-Pagán B, Lam AT, **O'Neal WK**, Blackman SM, Knowles MR, Cutting GR. 2020. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR. *Pediatr Pulmonol.* 55: S117-S118.
  6. Esther CR, O'Neal WK, Koch AL, Cooper CB, Barjaktarevic I, Raffield L, Bowler RP, Comellas AP, Peters SP, Curtis JL, Ronish B, Ortega VE, Wells JM, Halper-Stromberg E, Rennard SI, Boucher RC. 2020. Prolonged, Physiologically Relevant Concentrations of Nicotine and Nicotine Metabolites in Airways of Smokers. *Am J Respir Crit Care Med.* 201:A1907.
  7. Fawzy A, Woo HJ, Balasubramanian A, Barjaktarevic I, Barr R, Bowler RP, Comellas AP, Criner GJ, Dransfield MT, Han MK, Hoffman EA, Kanner RE, Krishnan JA, **O'Neal WK**, Paine R, Peters SP, Woodruff P, Hansel NN, Putcha N. 2020. Phenotypic Characteristics and Clinical Outcomes Among Individuals with COPD and Polycythemia. *Am J Respir Crit Care Med.* 201: A2855.
  8. Freeman CM, Brown JP, Kady MR, Stolberg VR, Toma MS, Alexis NE, Arjomandi M, Barjaktarevic I, Barr R, Bleecker ER, Bowler RP, Christenson S, Comellas AP, Couper D, Criner GJ, Doerschuk CM, Dransfield MT, Han MK, Hastie AT, Hoffman EA, Kaner RJ, Kaner RJ, Krishnan JA, Labaki WW, Martinez FJ, Meyers DA, **O'Neal WK**, Paine R, Tejwani V, Wells JM, Woodruff P, Curtis JL. 2020. Intermediate (CD14++CD16+) Monocytes Correlate with Parametric Response Mapping of Functional Small Airways Disease: Spiromics Immunophenotyping Sub-Study. *Am J Respir Crit Care Med.* 201: A1063.
  9. Hoesterey D, Dang H, Barr R, Belperio JA, Bowler RP, Buhr RG, Couper D, Criner GJ, Doerschuk CM, Dransfield MT, Drummond M, Freeman CM, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kaner RJ, Kanner RE, Kim V, Krishnan JA, Martinez FJ, **O'Neal WK**, Ortega VE, Paine R, Tashkin DP, Wells JM, Woodruff P, Curtis JL, Barjaktarevic I, Spiromics Investigators. 2020. Neutrophil to Lymphocyte Ratio (NLR) Is a Potential Biomarker in Clinically Stable Chronic Obstructive Pulmonary Disease: SPIROMICS Cohort. *Am J Respir Crit Care Med.* 201: A2857.
  10. Kato T, Okuda K, Cardenas BS, Gilmore RC, Thacker H, Goodell HP, Loznev HT, Radicioni G, Kesimer M, Randell S, Ballard ST, **O'Neal W**, Button B, Boucher R. 2020. Altered biophysical properties of SMG mucus and decreased prr4 in induced sputum suggest impaired SMG secretion in CF. *Pediatr Pulmonol.* 55: S40.
  11. Masters B, Curtis JL, Han MK, Martinez FJ, **O'Neal WK**, Freeman CM, Criner GJ, Dransfield MT, Bowler RP, Couper D, Labaki WW, Hansel NN, Peters SP, Woodruff P, Bhatt SP, Siler TM, Miller M, Herrera JE. 2020. Plasma GDF-15 Levels Improve Risk Assessments for Severe COPD Outcomes. *Am J Respir Crit Care Med.* 201: A2860.
  12. Morrison CB, Delion M, Markovetz MR, Quinney NL, Morton L, Gentzsch M, Hill DB, **O'Neal W**, Kesimer M, Ehre C. 2020. Modulator therapy normalizes CF mucus in vitro. *Pediatr Pulmonol.* 55: S40.
  13. Ngo D, Pratte KA, Flexeder C, Petersen H, Dang H, Ma Y, Keyes MJ, Peterson BD, Sitars V, Gillenwater LA, Xu H, Emson C, Gieger C, Suhre K, Graumann J, Jain D, Conomos MP, Tracy RP, Guo X, Liu Y, Johnson W, Cornell E, Durda P, Taylor KD, Papanicolaou GJ, Rich SS, Rotter JI, Rennard SI, Curtis JL, Woodruff P, Comellas AP, Silverman EK, Crapo JD, Larson MG, Ramachandran V, Wang TJ, Gerszten RE, O'Connor GT, Barr R, Couper D, Dupuis J, Manichaikul A, **O'Neal WK**, Tesfaigzi Y, Schulz H, Bowler RP. 2020. Systemic Biomarkers of Lung Function and FEV1 Decline Across Multiple Cohorts. *Am J Respir Crit Care Med.* 201: A5527.
  14. O'Beirne SL, Salit J, Alexis NE, Arjomandi M, Barjaktarevic I, Bowler RP, Christenson S, Curtis JL, Doerschuk CM, Drummond M, Hastie AT, Huang YJ, Kim V, **O'Neal WK**, Ortega VE, Wells JM, Woodruff P, Basta P, Crystal RG, Kaner RJ, Spiromics Investigators. 2020. Current Smoking Down-Regulates

- Specific Alveolar Macrophage Host Defense Gene Expression Pathways. *Am J Respir Crit Care Med.* 201: A1217.
15. Okuda K, Dang H, Kobayashi Y, Nakano S, Cardenas SMB, O'Neal VK, Kato T, Chen G, Gilmore RC, Quinney NL, Gentzsch M, Anderson C, Chua M, Andrew G, Randell S, Tata P, **O'Neal W**, Boucher R. 2020. Secretory cells dominate airway CFTR expression and function in superficial epithelia lining human airways. *Pediatr Pulmonol.* 55: S63.
  16. Okuda K, Kato T, Chen G, Gilmore RC, Chua M, Bittar HT, **O'Neal WK**, Wenzel SE, Boucher RC. 2020. Altered Secretory Mucin Expression in Systemic Steroid-Dependent Severe Asthma Small Airways. *Am J Respir Crit Care Med.* 201: A7466.
  17. Okuda K, Kobayashi Y, Dang H, Nakano S, Barbosa S, O'Neal VK, Kato T, Chen G, Gilmore RC, Quinney NL, Gentzsch M, Radicioni G, Kesimer M, Anderson C, Chua M, Ghio AJ, Randell SH, Tata P, **O'Neal WK**, Boucher RC. 2020. Mucin-Competent Secretory Cells Are a Major Cell Type for CFTR Expression in Normal Human Airway Epithelia. *Am J Respir Crit Care Med.* 201: A2663.
  18. Ortega VE, Barjaktarevic I, Li X, Ampleford E, **O'Neal WK**, Hawkins GA, Bowlers RP, Moore WC, Barr R, Cooper CB, Couper D, Han MK, Hansel NN, Kanner RE, Martinez FJ, Paine R, Woodruff P, Hoffman EA, Peters SP, Bleecker ER, Meyers DA, NHLBI S. 2020. Genome-Wide Association Study of Short-Acting Bronchodilator Response Identifies Novel Pharmacogenetic Loci in SPIROMICS. *Am J Respir Crit Care Med.* 201: A7826.
  19. Ortega VE, Kim D, Moore WC, Zein JG, Li X, Ampleford E, **O'Neal WK**, Bowler RP, Barr R, Barjaktarevic I, Castro M, Cooper CB, Couper D, Denlinger LC, Erzurum SC, Fahy JV, Fitzpatrick AM, Gaston BM, Han MK, Hansel NN, Hastie AT, Hoffman EA, Israel E, Jarjour NN, Kanner RE, Martinez FJ, Mauger D, Paine R, Levy BD, Wenzel SE, Woodruff P, Peters SP, Bleecker ER, Meyers DA, Liggett SB, Hawkins GA, NHLBI S, NHLBI S. 2020. Deep Resequencing of the Beta-2 Adrenergic Receptor Gene (ADRB2) in COPD and Asthma Cohorts Identifies Functional Rare Variants. *Am J Respir Crit Care Med.* 201: A4220.
  20. Putcha S, Gu T, Murray S, Meldrum CA, Cardenas-Garcia J, Curtis JL, Martinez FJ, Criner GJ, Bowler RP, Barr R, Hoffman EA, Fawzy A, Putcha N, Hansel NN, Bleecker ER, Barjaktarevic I, Kanner RE, Paine R, Dransfield MT, Krishnan JA, Ortega VE, Peters SP, **O'Neal WK**, Arjomandi M, Woodruff P, Han MK, Labaki WW. 2020. Patient-Reported Clinical Variables Associated with Significant Air Trapping in Smokers: An Analysis of the SPIROMICS Cohort. *Am J Respir Crit Care Med.* 201: A4564.
  21. Vameghestahbanati M, Hoffman EA, Couper D, Hansel NN, Oelsner E, Sack C, Woodruff P, **O'Neal WK**, Hamid Q, Barr R, Smith BM. 2020. Airway Tree Structure Modifies Cigarette Smoke-Associated Lung Function Decline. *Am J Respir Crit Care Med.* 201: A6407.
  22. Winters C, Radicioni G, Wilkinson K, Kesimer M, Boucher R, **O'Neal W**, Livraghi-Butrico A. 2020. Age and host microbiota affect the abundance and composition of airway mucus. *Pediatr Pulmonol.* 55:S45-S6.
  23. Yee N, Markovic D, Buhr RG, Tashkin DP, Bhatt SP, Fortis S, Arjomandi M, Ronish B, Couper D, Anderson WH, Kanner RE, Paine R, Kaner RJ, **O'Neal WK**, Woodruff P, Han MK, Martinez FJ, Barr R, Wells JM, Ortega VE, Hoffman EA, Kim V, Drummond M, Bowler RP, Criner GJ, Curtis JL, Coopers CB, Barjaktarevic I. 2020. Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort. *Am J Respir Crit Care Med.* 201: A6418.
  24. Zhou Y, Gallins P, Pace RG, Dang H, **O'Neal W**, Li Y, Ling H, Bamshad M, Gibson R, Cutting GR, Blackman SM, Wright F, Knowles M. 2020. Genetic modifiers of cystic fibrosis lung disease: Initial results from the Cystic Fibrosis Genome Project. *Pediatr Pulmonol.* 55: S117.
  25. Anderson WH, Quibrera M, **O'Neal WK**, Drummond MB, Alexis NE, Barjaktarevic I, Couper D, Bateman L, Paine R, Kaner RJ, Curtis JL, Woodruff P, Han MK, Martinez FJ, Barr RG, Hansel NN, Bleecker ER, Hoffman EA, Ortega VE, Doerschuk CM, Kim V, Dransfield MT, Bhatt SP, Bowler RP, Criner G, Cooper CB, Kanner RE, Boucher RC, Lazarowski E. 2019. Accelerated ATP hydrolysis in airway surface liquid (ASL) provides a mechanism for mucus dehydration in chronic bronchitis. *Am J Respir Crit Care Med.* 199: A3847.
  26. Bates M, Brown JP, Freeman CM, Stolberg VR, Kady M, Wang Y, Murray S, Alexis NE, Barjaktarevic I, Barr RG, Bleecker ER, Bowler RP, Christenson S, Comellas AP, Cooper CB, Couper D, Criner GJ,

- Doerschuk CM, Han MK, Hansel NN, Hastie AT, Hoffman EA, Huang YJ, Kaner RJ, Krishnan JA, Martinez FJ, Meyers DA, **O'Neal WK**, Paine R, Peters SP, Putcha N, Wells JM, Wilson N, Woodruff P, Curtis JL. 2019. Altered alveolar macrophage expression of Axl and Mertk in COPD: SPIROMICS Immunophenotyping Sub-Study. *Am J Respir Crit Care Med.* 199: A4040.
27. Brehm CE, Genese F, Marion CR, Li X, **O'Neal WK**, Newell JD, Hawkins GA, Barr RG, Cooper CB, Couper D, Han MK, Hansel NN, Kanner RE, Kleerup EC, Martinez FJ, Paine R, Woodruff P, Peters SP, Hoffman EA, Bleecker ER, Meyers DA, Ortega VE. 2019. Pathogenic primary ciliary dyskinesia pathway variants associate with disease severity in at-risk smokers and COPD subjects from SPIROMICS. *Am J Respir Crit Care Med.* 199: A4858.
28. Chen G, Sun L, Kato T, Okuda K, Martino ME, Abzhanova A, Lin JM, Gilmore RC, Batson B, O'Neal VK, Volmer A, Dang H, Deng Y, Randell SH, Button B, Livraghi-Butrico A, Kesimer M, Ribeiro CM, **O'Neal W**, Boucher R. 2019. IL1 beta is the dominant pro-mucin secretory cytokine in CF airway secretions. *Pediatr Pulmonol.* 54: S182-S3.
29. Cmielewski P, McCarron A, Reyne N, Finnie J, Rout-Pitt N, Schjenken J, Chen H, McIntyre C, Craig F, **O'Neal W**, Parsons D, Donnelley M. 2019. An update on the phenotype characterisation of Phe508del and CFTR knockout rats. *Pediatr Pulmonol.* 54: S168.
30. Dang H, Polineni D, Pace RG, Stonebraker JR, Corvol H, Cutting GR, Drumm ML, Strug LJ, **O'Neal W**, Knowles M. 2019. Novel CF modifier genes by expression imputation from GWAS and EQTL data. *Pediatr Pulmonol.* 54: S243.
31. Esther CR, **O'Neal WK**, Anderson WH, Kesimer M, Hastie AT, Barr RG, Bowler RP, Wells JM, Oelsner E, Boucher RC. 2019. Impaired mucus hydration and hydration signaling pathways in COPD. *Am J Respir Crit Care Med.* 199: A1126.
32. Genese F, Newell JD, **O'Neal WK**, Marion CR, Li X, Hawkins GA, Brehm CE, Barjaktarevic I, Barr RG, Cooper CB, Couper D, Han MK, Hansel NN, Kanner RE, Kleerup EC, Martinez FJ, Paine R, Woodruff P, Hoffman EA, Peters SP, Meyers DA, Bleecker ER, Ortega VE. 2019. The rare PI Z variant associates with bronchiectasis in non-Hispanic White at-risk current and ex-smokers and COPD subjects from SPIROMICS. *Am J Respir Crit Care Med.* 199: A3849.
33. Huang YJ, Opron K, Erb-Downward J, Begley L, Alexis NE, Barjaktarevic I, Barr RG, Bleecker ER, Bowler RP, Christenson S, Comellas AP, Cooper CB, Couper D, Doerschuk CM, Dransfield MT, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kaner RJ, Krishnan JA, **O'Neal WK**, Paine R, Peters SP, Wells JM, Woodruff P, Martinez FJ, Bates M, Freeman CM, Curtis JL, Huffnagle GB. 2019. Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. *Am J Respir Crit Care Med.* 199: A5578.
34. Kamath D, Budden T, Kim M, Baumlin N, **O'Neal W**, Knowles M, Weinman S, Salathe M, Polineni D. 2019. Anti-inflammatory effects of methylthioadenosine in cystic fibrosis. *Pediatr Pulmonol.* 54:S172.
35. Kato T, Okuda K, Cardenas SMB, Gilmore RC, Das J, Sun L, Lin JM, Nakano S, Chen G, Button B, Randell SH, Ballard ST, **O'Neal W**, Boucher R. 2019. Identification of submucosal gland-specific proteins as a marker of gland secretion. *Pediatr Pulmonol.* 54: S179.
36. Kelada SN, Li Y, Van Buren E, Radicioni G, Ford A, **O'Neal WK**, Ortega VE, Woodruff P, Bleecker ER, Boucher RC, Kesimer M. 2019. Genome-wide association study of sputum mucin concentrations in the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). *Am J Respir Crit Care Med.* 199:A2149.
37. Okuda K, Kobayashi Y, Dang H, Nakano S, Cardenas SMB, O'Neal VK, Kato T, Chen G, Gilmore RC, Chua M, Livraghi-Butrico A, Doerschuk C, Grubb B, Randell SH, Tata P, **O'Neal W**, Boucher R. 2019. Regional regulation of CFTR and ionocyte expression in normal human airways. *Pediatr Pulmonol.* 54:S173.
38. **O'Neal WK**, Putman RK, Wang JJ, Barjaktarevic I, Cooper CB, Cho MH, Couper DJ, Hansel NN, Hatabu H, Rosas IO, Nishino M, Ortega VE, Lynch DA, Woodruff PG, Barr RG, Curtis JL, Han MK, Bleecker ER, Kaner RJ, Paine R, Sidhaye VK, Silverman EK, Hoffman EA, Martinez FJ, Washko GR, Bowler RP, Hunninghake GM, Newell, JD; SPIROMICS (Spiromics); COPDgene. 2019. Distinct blood biomarkers associate with visual evidence of interstitial lung abnormality on HRCT in both SPIROMICS and COPDgene. *Am J Respir Crit Care Med.* 199:A5840.

39. Ortega VE, **O'Neal WK**, Newell JD, Li X, Hawkins GA, Barjaktarevic I, Barr RG, Cooper CB, Couper D, Han MK, Hansel NN, Kanner RE, Kleerup EC, Martinez FJ, Paine R, Scholand M, Woodruff P, Peters SP, Hoffman EA, Meyers DA, Bleecker ER. 2019. Genome-wide association study identifies novel loci and recapitulates known loci for interstitial lung disease in non-Hispanic Whites from SPIROMICS. *Am J Respir Crit Care Med.* 199:A4861.
40. Ortega VE, Li X, Ampleford E, **O'Neal WK**, Hawkins GA, Manichaikul A, Barjaktarevic I, Barr RG, Cooper CB, Couper D, Han MK, Hansel NN, Kanner RE, Kleerup EC, Martinez FJ, Paine R, Woodruff P, Hoffman EA, Peters SP, Bleecker ER, Meyers DA. 2019. Genome-wide association study of acute exacerbations of COPD identifies novel loci in SPIROMICS. *Am J Respir Crit Care Med.* 199:A4862.
41. Putcha N, Dransfield MT, LaFon D, Woo J, Azar A, Fawzy A, Cooper CB, Bowler RP, Comellas AP, Krishnan JA, Han MK, Couper D, Peters SP, Drummond MB, **O'Neal WK**, Criner GJ, Martinez FJ, Curtis JL, Barr RG, Woodruff P, Hansel NN. 2019. BAL and serum immunoglobulin G levels are associated with risk for exacerbations, clinical and CT phenotypes, an analysis of SPIROMICS. *Am J Respir Crit Care Med.* 199:A1580.
42. Radicioni G, Ford A, Ceppe A, Alexis NE, **O'Neal WK**, Boucher RC, Kesimer M, SPIROMICS Investigative Group. 2019. Cigarette smoke driven MUC5AC increase and airway obstructions in COPD. *Am J Respir Crit Care Med.* 199:A1127.
43. Subramani DB, Chen G, Okuda K, Haridass P, Wang B, Markovetz MR, Radicioni G, Christine LJ, Morrison CB, Fontana NC, Garbarine I, Winkler SS, Livraghi-Butrico A, Hill DB, Button B, **O'Neal W**, Kesimer M, Boucher R, Ehre C. 2019. CRISPR/CAS9 based cell lines (A549 and CALU-3 cells at single cell level) for human MUC5ACM and MUC5BM and its role in lung diseases. *Pediatr Pulmonol.* 54:S327.
44. Zhang W, Oromendia C, Kikkers SA, Kim K, **O'Neal WK**, Freeman CM, Christenson S, Peters SP, Wells JM, Doerschuk CM, Putcha N, Woodruff P, Cooper CB, Comellas AP, Criner GJ, Paine R, Hansel NN, Han MK, Han MK, Curtis JL, Kaner RJ, Ballman KV, Martinez FJ, Cloonan SM. 2019. Extracellular bronchoalveolar lavage fluid ferritin and risk for exacerbation in COPD: an analysis from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). *Am J Respir Crit Care Med.* 199:A5369.
45. Ash SY, Harmouche R, Putman RK, Ross JC, Martinez FJ, Choi AM, Bowler RP, Regan EA, Curtis JL, Han MK, Boucher RC, **O'Neal WK**, Hatabu H, Lynch DA, Rosas IO, Hunninghake GM, Estepar RS, Washko GR. 2018. Association between acute respiratory disease events and the MUC5B promoter polymorphism in smokers. *Am J Respir Crit Care Med.* 197:A2410.
46. Barjaktarevic I, Hu S, Couper D, Anderson WH, Kanner RE, Paine R, Kaner RJ, Curtis JL, **O'Neal WK**, Woodruff P, Postow L, Han MK, Martinez FJ, Barr R, Wells JM, Ortega VE, Hoffman EA, Doerschuk CM, Kim V, Dransfield MT, Bhatt SP, Bhakta NR, Drummond MB, Bowler RP, Criner GJ, Martinez C, Tashkin D, Cooper CB. 2018. Bronchodilator responsiveness in COPD: results from SPIROMICS. *Am J Respir Crit Care Med.* 197:A6395.
47. Bolourchi S, **O'Neal WK**, Kaner RJ, Doerschuk CM, Boucher RC, Criner GJ, Couper D, Bowler RP, Comellas AP, Dransfield MT, Krishnan JA, Barjaktarevic I, Paine R, Bleecker ER, Peters SP, Barr RG, Rennard SI, Raman SM, Hansel NN, Hoffman EA, Galban CJ, Curtis JL, Freeman CM, Martinez FJ, Han MK, Christenson S, Woodruff PG, Bhakta NR. 2018. Airway epithelial microRNAs associated with small airway dysfunction and Interleukin-17-driven inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 197:A7441.
48. Boucher RC, Ceppe AS, **O'Neal WK**, Ford A, Barr RG, Bleecker ER, Curtis JL, Cooper CB, Han MK, Hoffman EA, Martinez FJ, Paine R, Woodruff P, Smith BM, Kesimer M. 2018. Mucin-based metrics to quantitate and identify mucus component of peripheral airways obstruction in the SPIROMICS cohort. *Am J Respir Crit Care Med.* 197:A1209.
49. Burkes RM, Ceppe AS, **O'Neal WK**, Han MK, Curtis JL, Comellas AP, Criner GJ, Krishnan JA, Christenson S, Barr RG, Cooper CB, Barjaktarevic I, Paine R, Ortega VE, Wise RA, Hansel NN, Drummond M. 2018. Low plasma cathelicidin levels are associated with reduced lung function and prior COPD exacerbations: an analysis of the SPIROMICS cohort. *Am J Respir Crit Care Med.* 197:A7442.
50. Choi S, Haghighi B, Hoffman EA, Newell JD, Comellas AP, Barr R, Han MK, Cooper CB, **O'Neal WK**, Woodruff P, Martinez FJ, Bleecker ER, Bowler RP, Krishnan JA, Kanner RE, Paine R, Peters SP,

- Dransfield MT, Hansel NN, Criner GJ, Couper D, Bhatt SP, Lin C. 2018. QCT imaging-based clusters of former smokers identify clinical phenotypes in the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). *Am J Respir Crit Care Med.* 197:A6387.
51. Freeman CM, Hoffman EA, Alikaj H, Stolberg VR, Alexis NE, Bleecker ER, Bowler RP, Christenson S, Comellas AP, Cooper CB, Couper D, Doerschuk CM, Han MK, Hansel NN, Hastie AT, Kaner RJ, Martinez FJ, Meyers DA, **O'Neal WK**, Paine R, Peters SP, Wells JM, Woodruff P, Barr RG, Curtis JL. 2018. Increased endothelial cell damage and decreased endothelial cell repair are implicated in emphysema pathogenesis: SPIROMICS Immunophenotyping Sub-Study. *Am J Respir Crit Care Med.* 197:A7439.
  52. Genese F, Ortega VE, Marion CR, **O'Neal WK**, Newell JD, Barr RG, Cooper CB, Couper D, Han MK, Hansel NN, Kanner RE, Martinez FJ, Meyers DA, Woodruff P, Peters SP, Hoffman EA, Bleecker ER. 2018. Risk factors and implications of bronchiectasis on COPD severity in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). *Am J Respir Crit Care Med.* 197:A3544.
  53. Haghighi B, Choi S, Choi J, Li F, Hoffman EA, Comellas AP, Newell JD, Barr R, Han MK, Bleecker ER, Cooper CB, Couper D, Hansel NN, Kanner RE, Kazerooni E, Martinez FJ, **O'Neal WK**, Paine R, Rennard SI, Woodruff P, Lin C. 2018. Imaging-based cluster analysis using novel metrics in COPD for Sub-Phenotyping of Current Smokers: SPIROMICS. *Am J Respir Crit Care Med.* 197:A1033.
  54. Kraft J, Jeong S, Zhao H, Kesimer M, Boucher RC, Christenson S, Comellas AP, Bateman LA, Britt A, Doerschuk CM, Dransfield MT, Han MK, Paine R, Cooper CB, Huang YJ, Barjaktarevic I, Moore WC, Nguyen CP, Morris C, Crystal RG, Curtis JL, Hastie AT, Kaner RJ, **O'Neal WK**, Ortega VE, Peters SP, Postow L, Rennard SI, Woodruff P, Kim V. 2018. Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD Subjects: an analysis of the SPIROMICS Cohort. *Am J Respir Crit Care Med.* 197:A2283.
  55. Labaki WW, Martinez CH, Freeman CM, Martinez FJ, Wells JM, Bhatt SP, Dransfield MT, Cooper CB, Putcha N, Hansel NN, Bleecker ER, Meyers DA, Pirozzi CS, Kanner RE, Paine R, Couper DJ, **O'Neal WK**, Barr RG, Woodruff PG, Ampleford EJ, Ortega VE, Curtis JL, Han MK. 2018. Higher levels of growth differentiation factor 15 (GDF-15) are associated with lower walking distance and exercise capacity in COPD: an analysis of the SPIROMICS cohort. *Am J Respir Crit Care Med.* 197:A3124.
  56. Manichaikul A, Nguyen JN, Christenson S, Tew W, Neighbors M, Garudadri S, Nerella S, Hoffman EA, Farber CR, Cho MH, **O'Neal WK**, Woodruff P, Wain LV, Rotter JI, London S, Im H, Rich SS, Barr RG. 2018. Genomic and transcriptomic analysis of pulmonary function and emphysema on CT scan. *Am J Respir Crit Care Med.* 197:A4187.
  57. Masters B, Han MK, Martinez FJ, Woodruff P, Criner GJ, Peters SP, Hansel NN, Comellas AP, Curtis JL, Paine R, **O'Neal WK**, Herrera JE, Miller M, Copeland K. 2018. Blood biomarker algorithms as an aide to describe exacerbations activity in symptomatic smokers and early staged COPD patients. *Am J Respir Crit Care Med.* 197:A2747.
  58. Okuda K, Chen G, Kato T, Wolf M, Gilmore R, Burns K, Chua M, Livraghi-Butrico A, Ehre C, Doerschuk CM, Randell SH, Matsui H, Nagase T, **O'Neal WK**, Boucher RC. 2018. Regional expression of secretory mucins MUC5AC and MUC5B in normal human airways. *Am J Respir Crit Care Med.* 197:A7636.
  59. Ortega VE, Hawkins GA, Li X, **O'Neal WK**, Manichaikul A, Barr R, Cooper CB, Couper D, Curtis JL, Han MK, Hansel NN, Kanner RE, Martinez FJ, Paine R, Wells JM, Woodruff P, Hoffman EA, Peters SP, Meyers DA, Bleecker ER. 2018. Comprehensive gene resequencing of SERPINA1 in SPIROMICS reveals novel rare loci for alpha 1-antitrypsin deficiency and emphysema. *Am J Respir Crit Care Med.* 197:A4184.
  60. Putcha N, Fawzy A, Matsui E, Bowler RP, Woodruff P, **O'Neal WK**, Comellas AP, Han MK, Dransfield MT, Lugogo N, Hoffman EA, Cooper CB, Hersh CP, Paulin LM, Drummond M, Wise RA, Diette GB, Hansel NN. 2018. Allergen sensitization and exposure is associated with exacerbations in COPD. *Am J Respir Crit Care Med.* 197:A2750.
  61. Dang H, Polineni D, Pace RG, Stonebraker JR, Li Q, Corvol H, Cutting GR, Drumm ML, Strug LJ, **O'Neal W**, Knowles M. 2017. Identification of novel CF modifier genes and pathways by expression imputation from GWAS. *Pediatr Pulmonol.* 52:S263.

62. Esther CR, Polineni D, Mahon A, Isaacman S, Bonfield TL, Knowles M, **O'Neal W**. 2017. A novel therapeutic targeting the methionine salvage pathway reduces airway inflammation. *Pediatr Pulmonol*. 52:S328-S329.
63. Mok H, Freeman CM, Martinez CH, Stolberg VR, Alexis NE, Barr RG, Bleecker ER, Bowler RP, Carretta EE, Christenson SA, Cooper CB, Couper DJ, Doerschuk CM, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kaner RJ, Martinez FJ, Meyers DA, **O'Neal WK**, Paine R, Putcha N, Rennard SI, Woodruff PG, Curtis JL. 2017. Active smoking is associated with decreased Cd4+T cells in bronchoalveolar lavage: Spiromics Immunophenotyping Sub-Study. *Am J Respir Crit Care Med*. 195:A2629.
64. Okuda K, Chen G, Wolf M, Burns K, Chua M, Livraghi-Butrico A, Ehre C, Doerschuk C, Randell S, **O'Neal W**, Boucher RC. 2017. Localization of secretory mucins MUC5AC and MUC5B in normal human airways. *Pediatr Pulmonol*. 52:S238-S239.
65. Okuda K, Chen G, Wolf M, Burns K, Chua M, Livraghi-Butrico A, Ehre C, Doerschuk C, Randell S, **O'Neal W**, Boucher RC. 2017. Localization of secretory mucins MUC5AC and MUC5B in normal human airways. *Pediatr Pulmonol*. 52:S238-S239.
66. Polineni D, Dang H, Gallins P, Jones L, Pace RG, Stonebraker JR, Corvol H, Cutting GR, Drumm ML, Strug LJ, Boyle MP, Durie P, Chmiel J, Zhou Y, Zou F, Wright F, **O'Neal W**, Knowles M. 2017. Nasal transcriptomic studies combined with genomic analyses identify gene networks associated with cystic fibrosis lung disease severity. *Pediatr Pulmonol*. 52:S263-S264.
67. Stonebraker JR, Dang H, Pace RG, Boyles S, Quinney N, Cholon DM, Harris A, Li Q, Randell S, Gentsch M, Knowles M, **O'Neal W**. 2017. EXPLORING the biologic basis of the chr11p13 CF lung disease modifying locus using CF airway epithelial cells. *Pediatr Pulmonol*. 52:S265.
68. Subramani DB, Shenoy SK, Wang B, Markovetz MR, Chen G, Radicioni G, Haridass P, Jones L, Garbarine IC, Winkler SS, Sears PR, Ostrowski LE, Livraghi-Butrico A, Esther CR, Hill DB, **O'Neal W**, Kesimer M, Button B, Boucher RC, Ehre C. 2017. Adhesive, cohesive and viscoelastic properties of MUC5AC play a role in CF pathogenesis. *Pediatr Pulmonol*. 52:S279.
69. Wells JM, Parker M, Osteri RA, Bowler RP, Dransfield MT, Cho MH, Woodruff PG, Kim V, Curtis JL, Martinez FJ, Paine R, Barri RG, Han MK, **O'Neal WK**, Castaldi PJ, Gaggari A. 2017. Elevated matrix metalloprotease 9 in moderate to severe COPD: results from Spiromics and Eclipse. *Am J Respir Crit Care Med*. 195: A2732.
70. Ancy KM, Leidy NK, Malley KG, Anderson WH, Barr RG, Bleeker E, Bowler RP, Carretta EE, Cooper CB, Couper DJ, Doerschuk CM, Dransfield MT, Hansel NN, Hoffman EA, Kanner R, **O'Neal WK**, Paine R, Peters SP, Scholand M, Woodruff PG, Han MK, Martinez FJ. 2016. How 'stable' is stable COPD? Daily symptom variability of subjects enrolled in the SPIROMICS Exacerbation Sub-Study. *Am J Respir Crit Care Med*. 193:A3527.
71. Anderson WH, **O'Neal WK**, Doerschuk CM, Carretta EE, Couper DJ, Tashkin D, Paine, III R, Cooper CB, Bleecker ER, Barr RG, Hansel NN, Han MK, Martinez FJ, Curtis JL, Woodruff PG, Kleerup E, Kanner R. 2016. Short-term stability of pulmonary function and clinical measures in COPD using a cohort from Spiromics (Subpopulations and Intermediate Outcome Measures in COPD Study). *Am J Respir Crit Care Med*. 193:A3515.
72. Barjaktarevic I, Martinez CH, Curtis JL, Bowler RP, **O'Neal WK**, Hoffman EA, Carretta EE, Quibrera M, Barr RG, Bleecker E, Couper DJ, Criner GJ, Dransfield MT, Han MK, Hansel NN, Kanner R, Lazarus SC, Martinez FJ, Paine R, Tashkin DP, Woodruff PG, Cooper CB. 2016. Biomarker characterization of a debilitated phenotype in Spiromics. *Am J Respir Crit Care Med*. 193: A1426.
73. Barjaktarevic I, Martinez CH, Curtis JL, Hoffman EA, Carretta EE, Bowler RP, **O'Neal WK**, Quibrera M, Barr RG, Martinez FJ, Couper DJ, Criner GJ, Dransfield MT, Han MK, Hansel NN, Kanner R, Lazarus SC, Bleecker ER, Paine R, Tashkin DP, Woodruff PG, Cooper CB. 2016 Identification of a debilitated phenotype in Spiromics. *Am J Respir Crit Care Med*. 193:A3519.
74. Brown JP, Freeman CM, Crudgington SW, Stolberg VR, Sonstein J, Alexis NE, Basta PV, Carretta EE, Christenson S, Couper DJ, Doerschuk CM, Hansel NN, Han MK, Hastie AT, Kaner RJ, Martinez FJ, **O'Neal WK**, Paine R, Rennard SI, Shimbo D, Woodruff PG, Zeidler M, Curtis JL. 2016. Current smoking increases macrophage numbers and immunoregulatory receptor expression in bronchoalveolar lavage but not sputum in chronic obstructive pulmonary disease: Spiromics Immunophenotyping Sub-Study. *Am J Respir Crit Care Med*. 193:A1432.

75. Chen G, **O'Neal WK**, Deng Y, Yu D, Jones L, Ribeiro C, Randell SH, Boucher RC. 2016. Il1r1 regulates Muc5b production and inflammatory responses in the airway epithelium. *Am J Respir Crit Care Med.* 193:A5559.
76. Chen G, Volmer A, Wilkinson K, Terrell K, **O'Neal WK**, Livraghi-Butrico A, Boucher RC. 2016. Spdef-independent mucin production during non-Th2-dominated pulmonary inflammation revealed in the Scnn1b-Tg muco-obstructive mouse model. *Am J Respir Crit Care Med.* 193:A5558.
77. Ford AA, Radicioni G, Cao R, Ceppe A, Doerschuk CM, **O'Neal WK**, Anderson WH, Boucher RC, Kesimer M. 2016. Mucin hypersecretion associated with chronic bronchitis and not emphysema in sputum from COPD patients from the SPIROMICS Cohort. *Am J Respir Crit Care Med.* 193:A3518.
78. Haghighi B, Choi S, Hoffman EA, Newell J, Barr RG, Han MK, Cooper CB, **O'Neal WK**, Woodruff PG, Bleecker ER, Martinez FJ, Lin CL. 2016. Multiscale imaging-based clusters in the COPD Cohort associates with clinical characteristics: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). *Am J Respir Crit Care Med.* 193:A6612.
79. Kelada S, Livraghi-Butrico A, McFadden K, Thomas J, **O'Neal WK**, Boucher RC. 2016. Quantitative genetic analysis of MUC5AC and MUC5B in a mouse model of asthma. *Am J Respir Crit Care Med.* 193:A2916.
80. Li SX, Hirzel AJ, Freeman CM, Crudgington SW, Stolberg VR, Sonstein J, Alexis NE, Basta PV, Carretta EE, Christenson SA, Couper DJ, Doerschuk CM, Han MK, Hansel NN, Hastie AT, Kaner RJ, Martinez FJ, **O'Neal WK**, Paine R, Rennard SI, Shimbo D, Woodruff PG, Zeidler M, Curtis JL. 2016. Active smoking is associated with increased eosinophils in bronchoalveolar lavage but not in sputum or peripheral blood: SPIROMICS Immunophenotyping Sub-Study. *Am J Respir Crit Care Med.* 193:A6345.
81. Livraghi-Butrico A, Grubb B, Ehre C, Ostrowski LF, Button B, Rogers T, Wilkinson K, Samir S, Villalon DG, Hale A, **O'Neal WK**, Thelin W, Boucher RC. 2016. Scnn1b-TG mice: a unique model to test airway mucus-mobilizing therapies in vivo. *Pediatr Pulmonol.* 51:284-5.
82. Martinez CH, Freeman CM, Nelson JD, Anderson WH, Bowler RP, Cooper CB, Couper DJ, Han MK, Martinez FJ, **O'Neal WK**, Ortega VE, Paine R, Woodruff PG, Curtis JL. 2016. Chronic bronchitis and airway thickening are associated with higher levels of growth differentiation factor-15 (GDF-15) in smokers without airflow obstruction: an analysis of the SPIROMICS Cohort. *Am J Respir Crit Care Med.* 193:A3510.
83. Ortega VE, Li X, **O'Neal WK**, Pennington EJ, Barr RG, Couper DJ, Han MK, Kanner R, Kleerup E, Martinez FJ, Peters SP, Rennard SI, Woodruff PG, Hoffman EA, Meyers DA, Bleecker ER. 2016. Rare *SERPINA1* variants in the multi-ethnic Spiromics population. *Am J Respir Crit Care Med.* 193:A4433.
84. Polineni D, Dang H, Pace RG, Stonebraker JR, Guo XG, Jones LC, Esther CR, Boyle MP, Chmiel JF, Durie PR, Gallins PJ, Wright FA, **O'Neal WK**, Knowles M. 2016. In vivo cystic fibrosis (CF) nasal epithelial transcriptomic studies reveal non-CFTR differential gene expression associated with CF Lung disease severity. *Am J Respir Crit Care Med.* 193:A6458.
85. Polineni D, Dang H, Pace R, Stonebraker JR, Jones L, Boyle MP, Chmiel J, Durie PR, Gallins, p C., Wright F, **O'Neal WK**, Knowles MK. 2016. Age of onset of chronic *P. aeruginosa* pulmonary infection is associated with differential gene expression in CF nasal epithelia in vivo. *Pediatr Pulmonol.* 51 Suppl 45:244.
86. Taylor J, Degtiar I, Murray S, Wang X, Martinez CH, Erb-Downward JR, Marchetti N, Criner GJ, **O'Neal WK**, Couper DJ, Bowler RP, Scholand M, Pirozzi C, Cooper CB, Kanner R, Paine R, Barr RG, Bleecker E, Hansel NN, Woodruff PG, Hoffman EA, Galban C, Ross BD, Kazerooni E, Martinez FJ, Han MK. 2016. Association between blood biomarkers, CT phenotype and COPD stage in SPIROMICS. *Am J Respir Crit Care Med.* 193:A4066.
87. Tew W, Chung C, Manser P, Holweg C, Christenson SA, Rosenberger C, **O'Neal WK**, Woodruff PG, Neighbors M. 2016. Serum type 2 chemokines in chronic obstructive pulmonary disease (COPD) subjects in the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). *Am J Respir Crit Care Med.* 193:A7873.
88. Anderson WH, Basta P, Carretta E, Cui G, Davis S, Doerschuk CM, Barr RG, Bleecker ER, Bowler RP, Curtis JL, Drummond MB, Han MK, Hansel NN, Kanner RE, Kleerup EC, Martinez FJ, Paine R, Peters SP, Woodruff PG, Rennard SI, Couper D, **O'Neal WK**. 2015. Reliability of multiplex-based blood biomarkers in COPD subjects enrolled in Spiromics (Subpopulation and Intermediate Outcome Measures in COPD Study). *Am J Respir Crit Care Med.* 191:A2935.

89. Brown JP, Freeman CM, Crudginton S, Stolberg VR, Sonstein J, Alexis NE, Basta P, Carretta E, Couper D, Doerschuk CM, Hastie AT, Kaner RJ, **O'Neal WK**, Paine R, Rennard SI, Shimbo D, Woodruff PG, Zeidler MR, Curtis JL. 2015. Monocytoid macrophages comprise an increased percentage of both mononuclear phagocytes and all leukocytes in bronchoalveolar lavages of smokers: SPIROMICS Immunophenotyping Sub-Study. *Am J Respir Crit Care Med.* 191:A2930.
90. Carlson TD, Kinney GL, Woodruff PG, Hansel NN, Han MK, **O'Neal WK**, Tashkin DP, Bowler RP. 2015. The significance and clinical impact of marijuana use in the SPIROMICS Cohort. *Am J Respir Crit Care Med.* 191:A4487.
91. Dang H, Gallins PJ, Rhonda PG, Stonebraker JR, Fossum SL, Leir S, Harris A, **O'Neal WK**, Knowles MR. 2015. Re-sequencing GWAS region on chromosome 11 identified novel candidate genetic variants associated with modification of CF lung disease. *Pediatr Pulmonol.* 50 Suppl 41:250.
92. Fossum SL, Mutolo MJ, Yang R, Dang H, **O'Neal WK**, Knowles MR, Leir S, Harris A. 2015. Ets homologous factor regulates pathways controlling response to injury in the airway epithelial cells. *Pediatr Pulmonol.* 50 Suppl 41:253.
93. Gupta R, Abdelwahab S, Jones L, Dang H, **O'Neal WK**, Kesimer M. 2015. Intercellular communication between the airway epithelial cells is mediated by exosomes like vesicles. *Am J Respir Crit Care Med.* 191:A3660.
94. Jacobson S, Kechris K, Sun W, Yang J, Chen TH, Barr RG, Basta P, Bleecker ER, Couper D, Curtis JL, Doerschuk CM, Drummond MB, Han MK, Hansel NN, Hawkins G, Hoffman EA, Kanner R, Kleeup EC, Martinez FJ, Meyers DA, **O'Neal WK**, Peters SP, Rennard SI, Woodruff PG, Bowler RP. 2015. Blood biomarker quantitative trait loci in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 191:A3627.
95. Keene J, Curtis JL, Doerschuk CM, Kinney GL, Foreman MG, Black-Shinn JL, Han MK, Kechris K, Woodruff PG, **O'Neal WK**, Barr RG, Rennard SI, Bleecker ER, Kleeup EC, Kanner R, Hansel NN, Jacobson S, Martinez FJ, Bowler RP. 2015. Blood biomarkers of exacerbations in the Spiromics and COPDgene Cohorts. *Am J Respir Crit Care Med.* 191:A5118.
96. Nguyen T, Chung F, **O'Neal WK**, Jones L, Gentsch M, Boucher R, Kreda SM. 2015. The effect of CFTR activity, bicarbonate, and pH on airway mucin secretion. *Pediatr Pulmonol.* 50 Suppl 41:214-5.
97. Polineni D, Esther CR, Pace RG, Stonebraker JR, Jones LC, Guo X, Boyle MP, Chmiel J, Durie PR, **O'Neal WK**, Knowles MR. 2015. In vivo human nasal lavage metabolomics suggest biomarkers of lung disease severity in cystic fibrosis. *Pediatr Pulmonol.* 50 Suppl 41:277.
98. Sesma JI, Livraghi-Butrico A, Wilkinson KJ, Weitzer C, Saini Y, Harden TK, **O'Neal WK**, Lazarowski ER. 2015. Blockage of the P2y14-receptor inhibits neutrophil infiltration in chronic lung diseases. *Am J Respir Crit Care Med.* 191:A6144.
99. Bailey KL, Han MK, Sayles HR, Barr RG, Doerschuk CM, Peters SP, Putcha N, Hansel NN, Woodruff PG, **O'Neal WK**, Couper D, Rennard SI. 2014. Patterns of biomarker expression in common comorbidities of COPD in the Spiromics population. *Am J Respir Crit Care Med.* 189:A5877.
100. Chen G, Martino ME, **O'Neal WK**, Boucher RC, Ribeiro CM. 2014. Role of the UPR in airway epithelial mucin production relevant to cystic fibrosis. *Pediatr Pulmonol.* 49 Suppl 38:255-6.
101. Duncan EA, Burns EN, Dang H, Jania CM, Tilley SL, Boucher RC, **O'Neal WK**, Doerschuk CM. 2014. Tobacco smoke causes oxidative stress and alterations in immune regulation in a murine model of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 189:A4289.
102. Han MK, Wang X, Murray S, **O'Neal WK**, Doerschuk CM, Anderson WH, Basta P, Couper D, Bowler RP, Weir M, Scholand MB, Pirozzi CS, Kleeup E, Kanner RE, Barr G, Bleecker ER, Martinez FJ, Woodruff PG, Hoffman EA. 2014. Blood biomarkers and CT phenotypes in the Subpopulations and Intermediate Outcome Measures in COPD Study (Spiromics). *Am J Respir Crit Care Med.* 189:A5915.
103. Nguyen T, Jones L, **O'Neal WK**, Boucher RC, Kreda SM. 2014. Airway mucin secretion is affected only indirectly by CFTR activity. *Pediatr Pulmonol.* 49 Suppl 38:265.
104. **O'Neal WK**, Anderson WH, Bowler R, Peters SP, Couper D, Rennard SI. 2014. Persistent systemic inflammation in the Spiromics COPD population. *Am J Respir Crit Care Med.* 189:A5918.
105. **O'Neal WK**, Wolf W, Jones LC, Gallins PJ, Pace RG, Stonebraker JR, Dang H, Wright F, Knowles MR. 2014. Differential gene expression identifies genetic modifiers associated with lung disease severity and age of onset of persistent pseudomonas infection in cystic fibrosis. *Am J Respir Crit Care Med.* 189:A6717.

106. Pirozzi CS, Scholand MB, Han MK, Cui G, Carretta E, **O'Neal WK**, Barr RG, Paine R, Kanner R. 2014. Low and high body mass index are associated with specific COPD phenotypes. *Am J Respir Crit Care Med*. 189:A5936.
107. Polineni D, Dang H, Gallins PJ, Pace RG, Stonebraker JR, Jones LC, Guo X, Boyle MP, Chmiel JF, Drumm ML, Durie PR, Wright FA, **O'Neal WK**, Knowles MR. 2014. In vivo human nasal epithelia inform transcriptomic studies in cystic fibrosis (CF) complementary to genomic variation studies. *Pediatr Pulmonol*. 49 Suppl 38:272.
108. Polineni D, Dang H, Pace RG, Stonebraker JR, Guo XL, Jones LC, Boyle MP, Chmiel J, Drumm M, Durie PR, Gallins PJ, Wright FA, **O'Neal WK**, Knowles MR. 2014. Correlation of inflammatory markers in human nasal epithelia in vivo informs transcriptomic studies in cystic fibrosis (CF) complementary to genomic variation studies. *Am J Respir Crit Care Med*. 189:A5519.
109. Terryah S, Wilkinson K, **O'Neal WK**, Taylor J, Tarran R. 2014. A SPLUNC1-derived peptide reduces lung disease in SCNN1B mice. *Pediatr Pulmonol*. 49 Suppl 38:285-6.
110. Bove PF, Cheluvvaraju C, Dang H, Jones LC, Liu X, **O'Neal WK**, Randell SH, Schlegel R, Boucher RC. 2013. Alveolar type 2 cells co-cultured with fibroblasts and a rho kinase inhibitor promotes proliferation and maintains cell specific ion/liquid transport properties. *Am J Respir Crit Care Med*. 187:A3399.
111. Doerschuk CM, Carretta E, **O'Neal WK**, Anderson WH, Couper D, Curtis JL, Woodruff PG, Rennard SI, Barr G. 2013. Circulating leukocytes, erythrocytes, and platelets in SPIROMICS. *Am J Respir Crit Care Med*. 187:A1513.
112. Duncan EA, Burns E, Prabhu S, Livraghi-Butrico A, Hua X, Dang H, Tilley SL, Boucher RC, **O'Neal WK**, Doerschuk CM. 2013. The role of airway surface dehydration and tobacco smoke in the pathogenesis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 187:A4086.
113. Fletcher A, Livraghi-Butrico A, **O'Neal WK**, Grubb BR, Boucher RC, Evans C. 2013. Required roles for Muc5B, but not Muc5ac in mucociliary clearance and anti-bacterial defenses in the lungs. *Pediatr Pulmonol*. 48 Suppl 36:451.
114. Kreda SM, Moussa L, Nguyen T, Jones LC, Wilkinson KJ, Kelly EJ, **O'Neal WK**, Lazarowski ER, Boucher RC. 2013. Mucin secretion inhibition in vivo reduces air way mucus obstruction, infection, and Inflammation. *Pediatr Pulmonol*. 48 Suppl 36:238.
115. **O'Neal WK**, Wolf WE, Jones LC, Mayhew GM, Gallins PJ, Pace RG, Stonebraker JR, Dang H, Zhou Y, Sun W, Zou F, Wright FA, Knowles MR. 2013. Differential gene expression identifies CF genetic modifiers associated with severity of lung disease. *Pediatr Pulmonol*. 48 Suppl 36:264.
116. Polineni D, Guo X, Jones LC, Patrone MV, Pace RG, Stonebraker JR, Boyle MP, Chmiel JF, Durie PR, Drumm ML, **O'Neal WK**, Knowles MR. 2013. Transforming growth factor beta 1 (TGFB1) expression in vivo is correlated with interleukin 8 (IL8) expression in CF airway (nasal) epithelia. *Pediatr Pulmonol*. 48 Suppl 36:267.
117. Button B, Cai L, **O'Neal WK**, Ehre C, Rubinstein M, Boucher RC. 2012. The role of cell surface-attached mucins in airway health. *Pediatr Pulmonol*. 47 Suppl 35:252.
118. Dang H, Guo X, Polineni D, Jones LC, Pace RG, Knowles MR, **O'Neal WK**. 2012. MUC5AC reference genomic and mRNA structures from high-throughput sequencing data. *Pediatr Pulmonol*. 47 Suppl 35:282.
119. Kreda SM, Jones L, Moussa L, Fulcher L, Yunxiang Z, Hudson E, **O'Neal WK**, Randell SH, Lazarowski ER, Boucher RC. 2012. VAMP8 is the vesicle SNARE for mucin secretion in airway goblet cells. American Thoracic Society, San Francisco CA. *Am J Respir Crit Care Med*. 185: A6299.
120. Kreda SM, Moussa L, Jones L, Clapp P, **O'Neal WK**, Lazarowski ER, Boucher RC. 2012. Rock signaling is an important mediator of airway goblet cell mucin secretion. *Pediatr Pulmonol*. 47 Suppl 35:256.
121. Livraghi-Butrico A, Cao R, Kelly EJ, Evans CM, Boucher RC, **O'Neal WK**, Kesimer M. 2012. Airway mucin interactome composition in response to defective mucus clearance and genetic deletion of secreted mucins. *Pediatr Pulmonol*. 47 Suppl 35:253.
122. Livraghi-Butrico A, Duncan EA, Saini Y, Dang H, Doerschuk CM, **O'Neal WK**, Boucher RC. 2012. Mechanisms of host defense during mucus obstruction in *Scnn1b* transgenic mice, a mouse model of COPD. 54<sup>th</sup> Thomas L. Petty Aspen Lung Conference, "COPD and Lung Cancer. A Continuum of Airway Disease", Aurora, CO. *Proc Am Thorac Soc*. 9(2):82-3.
123. Saini Y, Dang H, Livraghi-Butrico A, **O'Neal WK**, Boucher RC. 2012. Macrophage activation patterns and development of airway inflammation in *Scnn1b*-transgenic mice. *Pediatr Pulmonol*. 47 Suppl 35:229.

124. Guo X, Dang H, Jones LC, Dang AT, **O'Neal WK**, Knowles MR. 2011. Relating respiratory mucin genes to CF lung disease severity: obtaining more accurate genetic maps and identification of functional variants. *Pediatr Pulmonol.* 46 Suppl 34:270.
125. Kreda SM, Jones L, Moussa, L, Fulcher L, **O'Neal WK**, Lazarowski ER, Boucher RC. 2011. VAMP8 is the v-SNARE that regulates airway mucin secretion. The 25th Annual North American Cystic Fibrosis Conference. *Pediatr Pulmonol.* 46 Suppl 34:246.
126. Kreda SM, **O'Neal WK**, Jones L, Moussa, L, Boucher RC, Lazarowski ER. 2011. Rho signaling and VAMP-8 are important mediators of airway goblet cell mucin secretion. Oral presentation; Gordon Research Conference "Cilia, Mucus & Mucociliary Interactions", Ventura CA, USA. **Carl Storm Award**
127. LaVange L, Greenberg J, Carretta E, Mostafa J, Deshmukh R, **O'Neal WK**, Rennard SI. 2011. The COPD ontology and its role in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). *Am J Respir Crit Care Med.* 183:A6011.
128. Livraghi-Butrico A, Duncan EA, Kelly EJ, Waxer DL, Gilmore RC, Evans CM, Doerschuk CM, Boucher RC, **O'Neal WK**. 2011. Deletion of *Muc5b* in *Scnn1b* transgenic mice reduces airway mucus obstruction but perturbs lung immune homeostasis: a new role for secreted mucins? *Pediatr Pulmonol.* 46 Suppl 34:239.
129. Livraghi-Butrico A, Grubb BR, Kelly EJ, Yang H, Geiser M, Boucher RC, **O'Neal WK**. 2011. Identification of congenic variant of *Scnn1b* transgenic mice reveals contribution of early lesions to the development of obstructive lung disease due to airway surface dehydration. *Pediatr Pulmonol.* 46 Suppl 34:271.
130. Livraghi-Butrico A, Kelly EJ, Klem E, Fulcher NB, Wolfgang MC, Boucher RC, Randell SH, **O'Neal WK**. 2011. Impaired mucus clearance correlates with increased susceptibility to spontaneous bacterial infection/colonization in *Scnn1b*-transgenic mice. American Thoracic Society International Conference, Denver, Colorado. *Am J Respir Crit Care Med.* 183:A1072.
131. Martino M, Brighton B, Dang H, **O'Neal WK**, Ribeiro CP. 2011. IRE1 $\beta$  regulates transcription of airway mucin genes and genes involved in mucin production and glycosylation. *Pediatr Pulmonol.* 46 Suppl 34:248-9.
132. **O'Neal WK**, Guo X, Dang H, Pace RG, Stonebraker JR, Polineni D, Gallins PJ, Jones LC, Dang AT, Doerschuk CM, Wright FA, Harris A, Knowles MR. 2011. From genes to function: exploring the mechanism of association between CF lung disease severity and genetic variation at Chr11p13. *Pediatr Pulmonol.* 46 Suppl 34:271.
133. Saini Y, Terrel K, Waxer D, Livraghi-Butrico A, **O'Neal WK**, Boucher RC. 2011. The roles of macrophages in determining the initiation, progression and resolution of lung inflammation in a mouse model of chronic bronchitis. *Pediatr. Pulmonol.* 46 Suppl 34:258.
134. Bove PF, Grubb BR, Okada SF, Randell SH, **O'Neal WK**, Boucher RC. 2010. Human alveolar type II cells secrete and absorb liquid in response to local luminal environmental signals. *Pediatr Pulmonol.* 45 Suppl 33:264.
135. Bove PF, Rogers TD, Brighton B, Ribiero CM, Randell SH, **O'Neal WK**, Grubb BR, Boucher RC. 2010. Ion transport and alveolar surface liquid regulation in human alveolar type II cells. *Am J Respir Crit Care Med.* 181:A6460.
136. Gilmore RC, Watson M, Jones L, **O'Neal WK**, Tarran R. 2010. A novel, high-throughput fret assay to monitor NF kappa B activation. *Pediatr Pulmonol.* 45 Suppl 33:295.
137. Kinev A, Clapp P, Tatreau JR, Jones L, Gilmore R, **O'Neal WK**, Randell SH. 2010. Differential involvement of NF-kappa B and C/EBP beta in acute versus chronic responses of human airway epithelium to *P. aeruginosa*. *Pediatr Pulmonol.* 45 Suppl 33:282.
138. Kreda SM, **O'Neal WK**, Jones L, Boucher RC, Lazarowski ER. 2010. VAMP-8 regulates mucin secretion in airway goblet cells. Poster. The 24th Annual North American Cystic Fibrosis Conference, Baltimore MD. *Pediatr Pulmonol.* 45 Suppl 33:248.
139. Kreda SM, Vidal-Seminario L, van Heusden CA, **O'Neal WK**, Jones L, Boucher RC, Lazarowski ER. 2010. Thrombin and neutrophil elastase promote nucleotide release from mucin granules in airway epithelial cells. Poster. The 10<sup>th</sup> International Symposium on Adenosine and Adenine nucleotides, Tarragona, Spain.
140. Livraghi-Butrico A, Kelly EJ, Evans CE, Boucher RC, **O'Neal WK**. 2010. Deletion of *Muc16*, *Muc5ac*, *Muc5b* in *Scnn1b* transgenic mice: implications for CF lung disease pathogenesis and therapy. *Pediatr Pulmonol.* 45 Suppl 33:258.

141. Livraghi-Butrico A, Kelly EJ, Klem E, Fulcher NB, Wolfgang MC, Boucher RC, Randell SH, **O'Neal WK**. 2010. Increased susceptibility to bacterial infection/colonization in *Scnn1b* transgenic mice. *Pediatr Pulmonol.* 45 Suppl 33:295.
142. Livraghi-Butrico A, Kelly EJ, Boucher RC, **O'Neal WK**, Randell SH. 2010. Non-redundant role of Toll-like receptor 2 and 4 in host defense and development of lung pathology when mucus clearance is impaired. *Pediatr Pulmonol.* 45 Suppl 33:281.
143. Martino MEB, Jones L, Brighton B, **O'Neal WK**, Ribeiro CMP. 2010. The ER stress transducer IRE1 $\beta$  is a key regulator of airway mucin production. *Pediatr Pulmonol.* 45 Suppl 33:256.
144. Watson M, Gilmore R, **O'Neal WK**, Gentzsch M, Tarran R. 2010. Adenosine 2B receptor signaling with CFTR is regulated by PDZ binding motifs on the C-terminus. *Pediatr Pulmonol.* 45 Suppl 33:226.
145. Cholon DM, **O'Neal WK**, Randell SH, Riordan JR, Gentzsch M. 2009. Apical recycling in primary human airway cells requires N-linked glycans and correct folding of CFTR. *Pediatr Pulmonol.* 44 Suppl 32:219.
146. Kreda SM, Vidal-Seminario L, van Heusden CA, **O'Neal WK**, Jones L, Boucher RC, Lazarowski ER. 2009. Thrombin and neutrophil elastase promote coordinated ATP and mucin release from airway epithelial cells. *Pediatr Pulmonol.* 44 Suppl 32:248-9.
147. Livraghi A, Hudson EJ, Wilkinson KJ, Boucher RC, Doerschuk CM, **O'Neal WK**. 2009. Identification of congenic *Scnn1b*-Tg lines markedly susceptible to pulmonary hemorrhage and right ventricular hypertrophy. *Pediatr Pulmonol.* 44 Suppl 32:279.
148. Livraghi A, Klem ER, Hudson EJ, Wilkinson KJ, Wolfgang MC, **O'Neal WK**, Boucher RC, Randell SH. 2009. Role of MyD88 and environmental bacteria in normal and pathologic airway development. *Am J Respir Crit Care Med.* 179:A2838.
149. Livraghi A, Wilkinson KJ, Hudson EJ, Randell SH, Boucher RC, **O'Neal WK**. 2009. Deletion of membrane-tethered mucins 1 and 4 does not alter the phenotype of *Scnn1b* transgenic mice: implications for airway mucin function. *Pediatr Pulmonol.* 44 Suppl 32:249.
150. Martino MB, Ehre C, **O'Neal WK**, Ribeiro CP. 2009. Role of the ER stress transducer IRE1 beta in airway inflammation-induced mucin production. *Pediatr Pulmonol.* 44 Suppl 32:259.
151. Bove PF, Trout L, Brighton B, **O'Neal WK**, Boucher RC. 2008. Coupling of alveolar to airway surfaces: studies using a transgenic CC10/EGFP secreted protein in alveolar epithelium. *Pediatr Pulmonol.* 43 Suppl 31:230.
152. Braun M, **O'Neal WK**, Xie M, Hurd H, Ribeiro CP. 2008. Selective inhibition of EIF2 alpha dephosphorylation reveals a key role for ER stress in airway inflammation. *Pediatr Pulmonol.* 43 Suppl 31:259.
153. Cholon DM, **O'Neal WK**, Riordan JR, Gentzsch M. 2008. Modulation of apical stability of rescued  $\Delta$ F508 CFTR in primary human airway epithelial cells. *Pediatr Pulmonol.* 43 Suppl 31:203.
154. Ehre C, **O'Neal WK**, Boucher RC. 2008. A mouse model to study the mechanisms and treatment of mucus adhesion in dehydrated airways. *Pediatr Pulmonol.* 43 Suppl 31:247.
155. Livraghi A, Grubb BR, **O'Neal WK**, Mall M, Boucher RC, Randell SH. 2008. Signaling pathways regulating the airway phenotype of mice exhibiting airway surface dehydration. Experimental Biology Meeting 2008, San Diego, CA. *FASEB J.* 22 Suppl 1:328-7.
156. Livraghi A, Klem ER, Hudson, EJ, Wilkinson KJ, Wolfgang MC, **O'Neal WK**, Boucher RC, Randell SH. 2008. Genetic deletion of MyD88-mediated signaling in  $\beta$ ENaC-overexpressing mice reduces airway neutrophilia but promotes spontaneous, mucus-associated bacterial infection. *Pediatr. Pulmonol.* 43 Suppl 31:262.
157. Livraghi A, Rogers TD, Brighton BW, Hudson EJ, Wilkinson KJ, Boucher RC, **O'Neal WK**, Grubb BR. 2008. Increased airway epithelial necrosis and massive airway neutrophilia in double CF/ $\beta$ ENaC mice highlights role for CFTR-mediated Cl<sup>-</sup> secretion in neonatal airways. *Pediatr. Pulmonol.* 43 Suppl 31:247.
158. Murray SA, Livraghi A, Sharp JE, Grubb BR, Hudson EJ, Wilkinson KJ, Jones LC, Boucher RC, **O'Neal WK**. 2008. Analysis of genetic modifiers of phenotypic severity in the  $\beta$ ENaC mouse model of cystic fibrosis. *Pediatr. Pulmonol.* 43 Suppl 31:270.
159. **O'Neal WK**, Hurd H, Wu Y, Braun M, Jones LC, Brighton B, Boucher RC, Ribeiro CM. 2008. Azithromycin alters the gene expression and inflammatory responses of human airway epithelia *Pediatr. Pulmonol.* 43 Suppl 31:243.
160. Sesma JI, Esther CR, Kreda SM, Jones LC, **O'Neal WK**, Nicholas R, Lazarowski E. 2008. Cellular release of UDP-sugars from the secretory pathway. *Pediatr. Pulmonol.* 43 Suppl 31:245.

161. Braun M, **O'Neal WK**, Ribeiro CP. 2007. Expansion of epithelial ER calcium stores during airway infection/inflammation is mediated by Upr-dependent Xbp-1. *Pediatr Pulmonol.* 42 Suppl 30:259-60.
162. Braun M, Tatreau J, Fulcher N, Wolfgang MC, Randell SH, **O'Neal WK**, Ribeiro CP. 2007. Pseudomonas aeruginosa activates the unfolded protein response in airway epithelia: relevance for airway inflammation. *Pediatr Pulmonol.* 42 Suppl 30:260.
163. Gentzsch M, **O'Neal WK**, Randell SH, Riordan JR. 2007. Endocytic trafficking of wild-type and  $\Delta$ F508 CFTR in highly differentiated primary cultures of human airway epithelia. *Pediatr Pulmonol.* 42 Suppl 30:217.
164. Grubb BR, Livraghi A, Rogers TD, Wilkinson KJ, Hudson EJ, Boucher RC, **O'Neal WK**. 2007. Enhancing Na<sup>+</sup> absorption in the airways of the CF mouse results in increased mortality. *Pediatr Pulmonol.* 42 Suppl 30:280-1.
165. Guo XL, **O'Neal WK**, Yeatts JP, Swallow DM, Pace RG, Stonebraker JR, Zariwala MA, Harris A, Wright FA, Zou F, Perez-Vilar J, Knowles MR. 2007. Assessing mucin gene polymorphisms to determine their role as modifiers of different CF phenotypes. *Pediatr Pulmonol.* 42 Suppl 30:265-6.
166. Jackson PL, Livraghi A, **O'Neal WK**, Noerager BD, Solomon GM, McQuaid DB, Gaggar A, Clancy JP, Sorscher EJ, Liu G, Abraham EA, Blalock JE, Rowe SM. 2007. Novel mediators of persistent neutrophilic inflammation in cystic fibrosis. *Pediatric Pulmonol.* 42 Suppl 30:229-30.
167. Livraghi A, Grubb BR, Hudson EJ, Wilkinson KJ, Mall M, **O'Neal WK**, Boucher RC, Randell SH. 2007. TNF $\alpha$  is not a key mediator of airway inflammation and remodeling in  $\beta$ ENaC-transgenic mice. *Pediatr Pulmonol.* 42 Suppl 30:257-8.
168. Livraghi A, Grubb BR, Threadgill DW, Mall MA, Hudson EJ, Boucher RC, **O'Neal WK**. 2007. Assessment of genetic modifiers for phenotypic severity of *Scnn1b* transgenic mice. *Pediatr Pulmonol.* 42 Suppl 30:266.
169. Livraghi A, Mall M, Rogers TD, Hudson EJ, **O'Neal WK**, Boucher RC, Grubb BR. 2007. Generation and phenotypic characterization of transgenic mice over-expressing multiple subunits of EnaC in the airways. *Pediatr Pulmonol.* 42 Suppl 30:239.
170. Livraghi A, Rogers TD, Wilkinson KJ, Hudson EJ, Boucher RC, **O'Neal WK**. 2007. Enhancing Na<sup>+</sup> absorption in the airways of the CF mouse results in increased mortality. *Pediatric Pulmonol.* 42 Suppl 30:280-1.
171. Mall M, Harkema JR, Trojanek JB, Treis D, Schubert S, Zhou Z, Tilley SL, Livraghi A, **O'Neal WK**, Boucher RC. 2007. Initial pulmonary lesions and spontaneous course of lung disease caused by airway surface liquid depletion in  $\beta$ ENaC overexpressing mice. *Pediatr Pulmonol.* 42 Suppl 30:279-80.
172. **O'Neal WK**, Winters SL, Stonebraker JR, Godfrey VL, Brighton BW, Jones LC, Hartwell HJ, Gilmore RC, Pickles RJ, Sheehan J, Davis C, Boucher RC. 2007. Deficiency of transmembrane mucin MUC4 reveals a potential role for MUC4 in determination of ciliary beat frequency. *Pediatr Pulmonol.* 42 Suppl 30:240.
173. Rowe SM, Solomon GM, Livraghi A, **O'Neal WK**, Gaggar A, Blalock JE, Clancy JP, Sorscher EJ, Abraham EA, Liu G. 2007. Evidence for pathogenic role of HMGB1 in cystic fibrosis. American Thoracic Society International Conference, San Francisco, CA. *Am J Respir Crit Care Med* 175:A448. 25.
174. Livraghi A, Hudson EJ, DeMaria GC, Sheehan JK, **O'Neal WK**, Boucher RC, Randell SH. 2006. Absence of IL-4R $\alpha$  in *Scnn1b*-transgenic mice enhances neonatal survival but does not mitigate adult lung pathology. *Pediatr Pulmonol.* 41 Suppl 29:246-7.
175. Livraghi A, **O'Neal WK**, Mall M, Boucher RC, Grubb BR. 2006. Enhanced Na<sup>+</sup> absorption in the double transgenic ENaC mouse *Scnn1b/c* correlates with severity of lung pathology. *Pediatr Pulmonol.* 41 Suppl 29:284.
176. Livraghi A, **O'Neal W**, Mall M, Boucher RC. 2005. Airway inflammation in *Scnn1b* transgenic mice. *Pediatr Pulmonol.* Suppl 28:261.
177. Holda JR, Pickles RJ, Burns KA, Gendler SJ, Boucher RC, **O'Neal WK**. 2001. Muc1 is a significant component of mouse airway luminal glycocalyx. North American Cystic Fibrosis Conference.
178. Mall M, Boucher RC, **O'Neal WK**. 2001. The novel ubiquitin-protein ligase Nedd 4.2 is co-expressed with the amiloride-sensitive Na<sup>+</sup> channel ENaC in human normal and CF airway epithelial cells. North American Cystic Fibrosis Conference.
179. Randell SH, **O'Neal WK**, Martsen EO, Noone PG, Zhou Z, Plonk MK, Wu Q, Knowles MR, Boucher RC, Gabriel SE. 2001. mRNA expression profiling of human airway epithelium. North American Cystic Fibrosis Conference.

180. Zhang YJ, **O'Neal WK**, Blackburn K, Moyer M, Moseley R, Boucher R, Ostrowski L. 2001. Identification and characterization of an axonemal dynein heavy chain reduced in cilia from a patient with primary ciliary dyskinesia. American Thoracic Society.
181. Lazarowski E, Grubb BR, **O'Neal WK**, Ribeiro CP, Burch N, Boucher RC. 2000. Regulation of gastrointestinal ion secretory responses by uridine nucleotide receptors. North American Cystic Fibrosis Conference.
182. Morse KM, **O'Neal WK**, Patel M, Davis CW, Olsen JC. 2000. An ecdysone-inducible expression system for use with retroviral vectors. *Mol Ther.* 1:S186-7.
183. **O'Neal WK**, Wang Y, Taylor K, Beaudet AL. 1997. Advantages of a-fetoprotein (AFP) as a reporter gene for expression in lung and liver in animals and humans. *Pediatr Pulmonol. Suppl* 14:187.
184. Lee B, Timme TL, Shine HD, **O'Neal WK**, Morral N, Zhou H, et.al. 1996. Toxicological studies of adenovirus mediated gene transfer via a) intracerebral and intraprostatic injection in non-human primates and cotton rats and b) systemic delivery into non-human primates, cotton rats, and mice. National Institute of Health, Gene Therapy Conference, Bethesda, MD, July 11-12.
185. Morral N, **O'Neal WK**, Zhou H, Langston C, Beaudet AL. 1996. Host responses to reporter genes complicate the interpretation of studies using adenoviral vectors. *Pediatr Pulmonol. Suppl* 13:168.
186. **O'Neal WK**, Beaudet AL. 1995. Adenovirus infection in MDCK polarized epithelial cells. Ninth Annual North American Cystic Fibrosis Conference, Dallas, TX, October 12-15.
187. Zhou H, Morral N, **O'Neal, WK**, Beaudet AL. 1995. Development of an adenoviral vector with deletions of E1 and E2a genes for CF gene therapy. *Pediatr Pulmonol. Suppl* 12:164.
188. **O'Neal WK**, Ecay T, Katkin J, Dubinsky W. 1994. Adenovirus-mediated expression of CFTR in MDCK cells. *Pediatr. Pulmonol. Suppl* 10:164.
189. **O'Neal WK**, Hasty EP, Liu K-Q, Casey BM, McCray PB Jr., Rivera-Perez J, Welsh MJ, Doyle NA, Doerschuk C, Bradley A, Beaudet AL. 1993. Characterization of mice with mutations in exons 2 and 3 or the cystic fibrosis gene. *Pediatr Pulmonol. Suppl* 9:138.
190. Beaudet AL, Wilson RW, Sligh JE, Ballantyne CM, Lemna (**O'Neal**) **WK**, Patejunas G, Hasty P, Bradley A, O'Brien WE. 1992. Applications of murine gene targeting to human genetics. *J Cell Biochem. Suppl* 16F:6.
191. Lemna (**O'Neal**) **WK**, Hasty EP, Beaudet AL, Bradley A. 1991. Toward a mouse model for cystic fibrosis. *Pediatr Pulmonol. Suppl* 6:50.
192. Beaudet AL, Feldman GL, Kobayashi K, Lemna (**O'Neal**) **WK**, Fernbach SD, O'Brien WE. 1990. Strategies for mutation analysis for cystic fibrosis. Fifth International Congress of Inborn Errors of Metabolism. Asilomar, June 1-5.

**Published Reviews, peer reviewed (from newest to oldest):**

1. **O'Neal WK**, Knowles MR. 2018. Cystic fibrosis disease modifiers: complex genetics defines the phenotypic diversity in a monogenic disease. *Annu Rev Genomics Hum Genet.* 19:201-222. PMID: 29709203.
2. Ribeiro CM, **O'Neal WK**. 2012. Endoplasmic reticulum stress in chronic obstructive lung disease. *Curr Mol Med.* 12:872-82. PMID: 22697344.
3. Randell SH, Fulcher ML, **O'Neal WK**, Olsen JC. 2011. Primary epithelial cell models for cystic fibrosis research. *Methods Mol Biol.* 742:285-310. PMID: 21547740.
4. **O'Neal WK**, Beaudet AL. 1994. Somatic gene therapy for cystic fibrosis. *Hum Mol Genet.* 3:1497-502. PMID: 7849744.
5. Beaudet AL, Feldman GL, Kobayashi K, **Lemna (O'Neal) WK**, Fernbach SD, Knowles MR, Boucher RC, O'Brien WE. 1991. Mutation analysis for cystic fibrosis in a North American population. *Adv Exp Med Biol.* 290:53-4. PMID: 1950757.

**6) Teaching Activities**

No formal teaching.

**7) Grants (Present and Completed)**

1/26/2022

ACTIVE

5 P30 DK 065988-17 (Boucher) 8/1/20-5/31/25  
NIH/NIDDK  
UNC Cystic Fibrosis Research and Translation Core Center, Core B: Molecular/Functional Measurement Core

The major goal of the overall P30 is to synergize and accelerate cystic fibrosis research by creating and supporting four research cores, a pilot and feasibility program and an administrative core to coordinate the activities. Cores include 1) Molecular and Functional Measurement Core focused on CFTR biogenesis/function and cystic fibrosis pathophysiology, 2) Cell Models Core focused on generation/provision of relevant airway and GI epithelial cell models, 3) Mucus Biochemistry/Biophysics Core, and 4) Human Translational Studies Core. Core B will provide support for translational cystic fibrosis research by evaluating pre-clinical drug candidates in vitro in cell cultures, ex vivo in organoid models, and in vivo in mouse models.

Role: Core Co-Director

2021-237918 (Hagood/Boucher/Hernandez/Kimple/Randell) 10/1/21-9/30/24  
The Chan Zuckerberg Initiative  
Mapping the Pediatric Inhalation Interface: Nose, Mouth and Airways

We will integrate respiratory system (RS) cellular transcriptomes and epigenomes, RS fluid secretomes, and RS microbiomes to describe and understand the healthy ecological landscape of the inhaled RS interface throughout childhood.

Role: Co-Investigator

AWD00002557 (134922-1) (Wenzel) 7/1/20-6/30/24  
Univ of Pittsburgh sub on NIH R01 HL153058  
Mucin sialylation drives epithelial cell senescence and severe asthma

This application explores the paradigm shifting hypothesis that post-translational modification (sialylation) of a cell surface (tethered) mucin, MUC4, drives terminal differentiation and senescence of airway epithelial cells (AECs) through inhibition of epidermal growth factor receptor (EGFR) family pathways, worsening epithelial wound repair and asthma severity. Our proposed studies will be the first to specifically test tethered mucins and their post-translational N-glycosylation/sialylation for a role in AEC terminal differentiation and senescence.

Role: Co-Investigator

5 U24 HL141762-04 (Couper & O'Neal) 8/15/18-7/31/23 2.4 calendar  
NIH/NHLBI \$1,074,023 annual direct costs  
SPIROMICS GIC Support

This application proposes infrastructure support for the Genomics and Informatics Center (GIC) and assistance to the clinical sites and investigators for the multi-center Sub-Populations and Intermediate Outcome Measures in COPD Study (SPIROMICS). The GIC will continue to manage SPIROMICS data and biospecimens, undertake statistical analyses of study data, collaborate in operational and scientific aspects of the study, and provide study management and regulatory oversight.

Role: MPI

5 U24 HL138998-04 (Ivanova/LaVange) 9/23/17-6/30/23  
NIH/NHLBI  
Data, Modeling, and Coordination Center for PrecISE Network

1/26/2022

The goal of this U24 application is to establish the Data, Modeling, and Coordination Center (DMCC) for the NHLBI's Precision Interventions for Severe and/or Exacerbation-Prone Asthma (PreclSE) Network. The objective of PreclSE is to conduct sequential, adaptive, phase II/proof of concept trials with precision interventions in stratified patient with severe asthma populations.

Role: Co-Investigator

BOUCHE19XX0 (Boucher)

2/1/20-1/31/23

Cystic Fibrosis Foundation

Abrogation of Airway Epithelial Barriers to Transduction, Project 1: Regions/Cell Types as Targets for CFTR Therapy

The UNC Collaborative Research Grant is designed to: 1) identify airway regional and cellular targets for CFTR nucleic acid therapy; 2) develop novel systems for their study; and 3) innovate techniques to overcome barriers. Three integrated projects attack these issues. Project 1 will 1) test findings that the Club cell is the dominant CFTR-expressing cell in small airways; 2) characterize the complex Club cell ion transport/mucin secretory functions; and 3) characterize Club cell nucleic acid transducibility.

Role: Co-Investigator

BOUCHE19R0 (Boucher)

7/1/19-6/30/23

0.60 calendar

Cystic Fibrosis Foundation

\$163,625 (Core E) annual direct costs

Epithelial Function in Cystic Fibrosis, Core E: Molecular Biology and Animal Models Core

The major goal of this core is to provide molecular biology materials, technical expertise and training and genetically modified mice relevant to cystic fibrosis research. These materials and support will further research efforts into CF within UNC and also by outside collaborators.

Role: Core Leader

PICKLE21G0 (Pickles)

2/1/21-1/31/23

Cystic Fibrosis Foundation

Do mucus secretions and airway inflammation protect the CF Lung from SARS2?

Because CF lung disease is so complex, with dehydrated mucus accumulating in the airways due to loss of the CFTR protein with inflammation and infection, we will use models of CF in mice infected with a SARS virus strain specifically adapted to infect mice. Using these models, we will explore three of the major features of CF lung disease: mucus, inflammation, and CFTR-deficiency. Increased mucus secretion might restrict access to target cells by inhaled viruses; the inflamed airway epithelium present in CF lungs might result in resistance of the epithelium to respiratory virus infection; and CFTR deficiency alone could alter cell and tissue homeostasis, which may render the cells more resistant or susceptible to virus infection and spread. We hypothesize excessive accumulation of dehydrated mucus secretions, pre-existing airway inflammation, and/or loss of CFTR function, as present in CF patients, alters SARS2 responses.

Role: Co-Investigator

22-0377 (O'Neal)

7/1/21-6/30/22

0.12 calendar

NHMRC (Synergy Australia) subcontract

\$17,062 annual direct costs

Comparison of fresh versus frozen epithelial cells for scRNA-seq analysis

Goal is to test fidelity of the freezing technique vs freshly isolated cell technique to inform the Synergy group as to best practices with respect to how to handle fresh transbronchoscopic brush epithelial and BAL samples for scRNAseq, and the congruence of culture sample scRNAseq data to data generated from deconvoluted bulk seq spatial transcriptomics analyses.

Role: PI

5 P01 HL108808-10 (Peden/Boucher)

7/1/20-6/30/22

NIH/NHLBI

1/26/2022

Development of Novel Mycolytic Therapies for Lung Disease, Project 2: PK/PD requirements for mucolytic therapeutic agents in vitro and in vivo

The overarching therapeutic goal for the UNC tPPG renewal is to clear the hyperconcentrated, adherent mucus that promotes airways obstruction, inflammation, and infection. Project 2 has focused on the hypotheses that: (1) hyperconcentrated (dehydrated) mucus produces airway mucus adhesion/plaques that drive the progression of muco-obstructive lung diseases; and, (2) that clearance of these plugs/plaques will be therapeutically useful in patients with the muco-obstructive phenotype. Thus the overarching goal of the 2b Project is to identify the optimal drug properties, balancing rate of mucin thiol reduction, duration of activity, and safety, to develop a new class of muco-clearance assisting agents that focus on mucin MW reduction that can be delivered alone or in combination with hydrating agents.

Role: Co-Investigator

Subcontract on R01 HL137995-01A1 (Bowler) 6/1/21-5/31/22 1.28 calendar  
National Jewish Health sub on NIH/NHLBI \$20,000 (sub only) annual direct costs  
Biomarkers of Lung Disease in African-Americans

The goals of the overall proposal are: (1) identify and replicate proteomic signatures for chronic obstructive pulmonary disease (COPD) disease progression (airflow limitation and emphysema) in African American (AA) and Whites and (2) integrate these proteomic signatures with other existing omics data to identify molecular networks associated with disease progression.

Subcontract PI

10454sc (Couper UNC, Woodruff, UCSF) 9/15/17-5/31/22  
UCSF, subcontract from NIH U01 HL137880  
SPIROMICS II

The UNC Collaborative Studies Coordinating Center will serve as the Data Coordinating Center (DCC) for the SPIROMICS II project. The DCC will be responsible for developing and maintaining study documents as well as creation/curation of the web-based data entry system.

Role: Co-Investigator

5 R01 HL136961-04 (Boucher) 8/1/17-5/31/22  
NIH/NHLBI  
Multiscale Biochemical/Biophysical Integration of Pulmonary Mucus Transport

We have selected four key gaps in our understanding of the mucociliary system for investigation. These gaps constitute our four specific aims. Specific Aim 1 How is mucin secretion organized intraregionally in superficial epithelia and proximally with submucosal gland secretion? Specific Aim 2: Are there functional differences in mucus secreted by superficial epithelia vs glands? Specific Aim 3: How are mucins released from granules onto the airway surface? Specific Aim 4: Why are mucins organized into gigantic (>100MD) higher-order multimers? The hypotheses tested are that gigantic molecules are required to generate mucus gels with biophysical properties commensurate with transport in dilute solutions and that such large molecules impose unique cell biologic packaging constraints on the cell. Importantly, resolution of the questions/hypotheses generated by this analysis of "gaps" in knowledge of the MCC system may lead to paradigm shifts in our understanding of normal MCC and how to approach novel therapies for bronchitic diseases.

Role: Co-Investigator

KNOWLES21XX0 (Knowles) 5/1/21-4/30/22  
Cystic Fibrosis Foundation  
Whole Genome Sequencing to Define Gene Modifiers in CF

The major goal of this project is to carry out whole genome sequencing on CF patients enrolled in multiple CFF studies from three separate sites.

1/26/2022

Role: Co-Investigator

PENDING

1 R01 AI172219-01 (Baric, Boucher MPI) 10/1/22-9/30/27

NIH/NIAID

Genetic and Molecular Regulation of SARS-CoV2 Induced Chronic Disease

The overall goal of this proposal is to understand the pathologic and molecular mechanisms governing Severe Acute Respiratory Coronavirus 2 (SARS-CoV2) mediated chronic lung disease, using mouse and deidentified human disease datasets. Our interdisciplinary team will test a variety of primary and secondary hypotheses designed to elucidate the underlying genetic, cellular, immunologic and molecular mechanisms that regulate/dysregulate acute to chronic disease progression in the lung after SARS-CoV2 infection.

Role: Co-Investigator

1 R01 AI155970-01A1 (Pickles) 7/1/22-6/30/27

NIH/NIAID

Clearance of Infectious Muco-Cellular Secretions during Viral Bronchiolitis

Our overarching hypothesis is that virus-infected epithelial cells shed into the airway lumen provide a potent inflammatory stimulus that potentiates inflammation and obstruction of the distal airways during viral bronchiolitis. Our goal is to identify novel therapeutic targets for reducing the accumulation of muco-cellular secretions in the virus-infected distal airways.

Role: Co-Investigator

1 R01 HL162988-01A1 (Boucher) 7/1/22-6/30/27

NIH/NHLBI

Pathogenesis of Non-CF Bronchiectasis

This application proposes a series of hypotheses to test a NCFB pathogenesis paradigm that describes elements both upstream and downstream of disease-producing mucus hyperconcentration. This application proposes 3 Specific Aims to test this paradigm: SA1: Test the hypothesis that bronchiolar muco-obstruction with airway epithelial hypoxia is a central component of the pathogenesis of the NCFB Syndrome. SA2: Test the hypothesis that chronic airway epithelial hypoxia produces paradoxical ion/fluid transport and mucin secretion and hyperconcentrated mucus in airway epithelia in vitro. SA3: Test the hypothesis that novel 19F-MRI technologies can detect NCFB bronchiolar disease.

Role: Co-Investigator

1 P01 HL164320-01 (Boucher, Rubinstein) 7/1/22-6/30/27

NIH/NHLBI

Multi-Scale Investigations of Respiratory Mucus/Mucin Structure and Function in Health and Disease, Project 2: Why are mucins so gigantic and is it safe/effective to sever them therapeutically?

The goal is to search for potential favorable effects of reducing multimer length on the mucus viscosity required for cough clearance and identify off-target effects mediated by reduction of other intra-mucin cysteines that may produce untoward mucin aggregation/stickiness. The deliverables of the project are to: 1) quantitate the relationships between mucin multimer size, space-occupying characteristics ( $c^*$ ), and mucus function in health; and 2) characterize the mucolytic agent therapeutic index with respect to on- vs off-target effects and provide a roadmap for development of novel mucolytic therapeutics for patients in need.

Role: Co-Investigator

1 U01 HL156655-01A1 (Boucher, Chen, Olivier) 12/1/21-11/30/25

NIH/NHLBI

1/26/2022

The molecular and cellular mechanisms of the STAT3 mutation-mediated pulmonary disorder in Autosomal Dominant Hyper IgE Syndrome (AD-HIES)

This application proposes to identify the molecular and cellular mechanisms underlying mutant STAT3 functional defects in innate immunity in airway epithelia and provide therapeutic options for new therapies for the pulmonary manifestations of autosomal dominant hyper IgE syndrome (AD-HIES).

Role: Co-Investigator

3 R01 HL155951-02S1 (Chen)

4/1/22-3/31/23

NIH/NHLBI

Role of alveolar KRT8+ transitional cells in promoting pulmonary fibrosis in response to SARS-CoV-2 infection

Our central hypotheses are that: 1) an abnormal AT2 transitional Krt8+ cell with features of hyperinflammation and reduced cell cycle/reparative capacity drives PF progression; and 2) this cell type is targetable by novel senolytic compounds that may prevent disease progression. We propose to test the hypothesis that persistence of alveolar Krt8+ transitional cells derived from ER stressed airway and/or AT2 progenitors drive late-stage PF and PASC. We will test this hypothesis by the following specific aims. Specific Aim1: Investigations of the cellular origin(s) and fates of the alveolar Krt8+ transitional cells following SARS-CoV-2 infection. Specific Aim2: Determine whether infected or non-infected (bystander) cells give rise to Krt8+ transitional cells in alveoli post SARS-CoV-2 infection.

Role: Co-Investigator

Admin Supp (Chen, Stripp)

4/1/22-3/31/23

Cedars-Sinai Medical Center sub on NHLBI

Chronic lung fibrosis as a sequelae of SARS-CoV-2 infection

The UNC subcontract team will conduct mouse exposure experiments, scRNAseq analyses, histological analyses, viral titers, and Luminex cytokine panels. They will perform 10x Genomics scRNA analyses of single cells and generate libraries and perform quality control and initial bioinformatics analyses of all scRNA seq data.

Role: Co-Investigator

3 R01 HL150541-03S1 (Livraghi-Butrico)

4/1/22-3/31/23

NIH/NHLBI

Mouse models to identify risks imposed by preexisting pulmonary diseases for development of prolonged COVID-19 Pulmonary sequelae

The major goals of this grant are to identify and characterize models of lung disease that: 1) predict lung disease-specific risks for COVID-19 pulmonary sequelae; and 2) accelerate therapeutics testing.

Role: Co-Investigator

## COMPLETED

NH19-OKUDA-1 (Okuda)

6/1/19-5/31/21

Cystic Fibrosis Research, Inc. New Horizons Grant

Regional regulation of CFTR and ionocyte expression in airways

The first aim reflects the source and distribution of CFTR in airways. We will systematically assess the regional distribution of pulmonary ionocytes and other possible cell types for CFTR expression in the proximal-distal axis of the human lung by RNA in situ hybridization, complemented by studies on rabbit and mice airways. The second aim reflects the potential regulation of pulmonary ionocyte expression under environmental stresses experienced by the airway epithelium. We will seek to clarify how the frequency of pulmonary ionocyte is altered under hyperosmotic, hypoxic and shear stress, utilizing primary airway epithelial cell cultures obtained from normal and CF human lungs.

1/26/2022

Role: Co-Investigator

KNOWLE18XX0 (Knowles) 6/1/18-4/30/21 (NCE)  
Cystic Fibrosis Foundation  
Discovery of CF Modifiers using Whole Genome Sequencing UNC

To discover CF modifiers, we will carry out whole genome sequencing (WGS) in 5,200 individuals with CF from the Gene Modifier Study (UNC), the Twin and Sibling Study (JHU), and the EPIC Observational Cohort Study (EPIC).

Role: Co-Investigator

COVID-19 Collaborative Grant (Boucher/O'Neal) 7/1/20-12/31/20 0.3 calendar  
State of North Carolina \$557,899  
Therapeutics II: Preclinical Studies of Novel Therapeutic Agents in Mouse Models for Target/Drug Validation, Pharmacokinetic (PK) Studies, and Efficacy Using Mouse-Adapted SARS-CoV-2 Virus, Project 1

We propose to create with the Baric lab a world-class in vivo mouse facility to test therapies to treat both components of COVID-19 disease: 1) the virus-dominated early damage phase; and 2) the late inflammation/repair phase. The Baric lab will focus on anti-viral approaches. The O'Neal lab component of a mouse therapeutics core focuses on the inflammation/repair components of COVID-19.

Role: Co-PI

5 UH3 HL 123645-05 (Boucher) 9/22/14-6/30/20 (NCE)  
NIH/NHLBI  
Synthesis of Effective and Safe Mucolytics for Pulmonary Disease

Our goal is to develop a novel mucolytic to be used as a single agent, or in combination of hydrating agents, to treat mucus retention in patients in need thereof. Strategies to optimize a lead compound and generate a clinical candidate are outlined in a four-tier approach in Specific Aim 1 that focus on both increases in safety and efficacy. Processes required to move the clinical lead to an IND are outlined in Specific Aim 2, including all of the IND requiring medicinal chemistry, toxicology, ADME, and PK studies.

Role: Co-Investigator

GRUBB17XX0 (Grubb) 4/1/17-3/31/20 (NCE) 0.60 calendar  
Cystic Fibrosis Foundation Therapeutics, Inc. \$349,909  
Characterizing the CF Rabbit

Our goal is to establish the feasibility of the CF rabbit as a model of spontaneous CF airway disease by extending the life and evaluating the longitudinal development of lung pathology.

Role: Co-PI

5 P30 DK 065988-15 (Boucher) 4/23/15-3/31/20  
NIH/NIDDK  
UNC Cystic Fibrosis Research and Translation Core Center, Core B: Pre-Clinical Core

The major goal of the overall P30 is to synergize and accelerate cystic fibrosis research by creating and supporting four research cores, a pilot and feasibility program and an administrative core to coordinate the activities. Cores include 1) Pre-Clinical Core focused on CFTR biogenesis/function, 2) Cell Models Core focused on generation/provision of relevant airway and GI epithelial cell models, 3) Mucus Biochemistry/Biophysics Core, and 4) Human Translational Studies Core. Core B will provide support for translational cystic fibrosis research by evaluating pre-clinical drug candidates in vitro in cell cultures, ex vivo in organoid models, and in vivo in mouse models.

Role: Core Co-Leader

1 R56 HL 136909-01A1 (Lazarowski) 9/21/18-8/31/19

1/26/2022

NIH/NHLBI

Regulation of Airway Mucus Hydration and Clearance by Released Nucleotides

The objective of this proposal is to investigate the contribution of nucleotide release and metabolism to mucin hydration in healthy and CB-stressed primary cultures of human and murine airway epithelial cells. Based on our preliminary data, we hypothesize that perturbations in ATP release and/or ecto-metabolic pathways govern mucus hydration responses to CB-related insults in airway epithelial cells.

\*Effort was 0.6 cm 9/21/18-8/31/19

Role: Co-Investigator

5 R01 HL 125280-04 (Button)

7/3/15-6/30/19

NIH/NHLBI

The Role of Mucus and Pulmonary Surface Intersections in Lung Disease

Our goal is to understand how the mucus and periciliary layers are maintained in health and why they fail in disease. In Aim 1 we will investigate the role of the PCL in airway defense; in Aim 2 we will perform studies to understand how mucus dehydration and neutrophil elastase alter the osmotic and cohesive properties of the mucus layer; and in Aim 3, we will combine the knowledge gained to understand how the mucus and PCL layers interact to maintain cilia- and cough-mediated mucus clearance and why they fail in disease.

Role: Co-Investigator

BOUCHE15R0 (Boucher)

7/1/15-6/30/19

0.60 calendar

Cystic Fibrosis Foundation

\$172,287 (Core E)

Epithelial Function in Cystic Fibrosis, Core E: Molecular Biology and Mouse Core

The major goal of this core is to provide molecular biology materials, technical expertise and training and genetically modified mice relevant to cystic fibrosis research. These materials and support will further research efforts into CF within UNC and also by outside collaborators.

Role: Core Leader

Research Contract (O'Neal)

12/10/18-5/31/19

0.24 calendar

Spirovation

\$19,321

Identification of TMEM16a in the Human Airway using RNAscope

The goal of this contract to conduct tests on the detection of RNA within fixed cells/tissue.

Role: PI

KNOWLE17G0 (Knowles)

11/1/17-10/31/18

Cystic Fibrosis Foundation

Exploring miRNAs for Regulating CF Lung Disease Severity

The goal of the project is to provide key information on miRNA expression that can be integrated with other datasets to develop further insight into the link between non-CFTR genetic variation and CF lung disease severity.

Role: Co-Investigator

DANG16I0 (Dang)

11/1/16-10/31/18

Cystic Fibrosis Foundation

Discovering CF Modifier Genes & Pathways by Expression Imputation from GWAS

We propose to impute genetically regulated gene expression from the CF GWAS data of 6,350 patient samples, and test CF disease phenotype association with much improved power to accelerate the discovery of modifier genes, which maybe targeted for intervention.

Role: Co-Investigator

1/26/2022

4 P01 HL 108808-05 (Boucher)

6/15/12-8/31/18

NIH/NHLBI

Novel Therapies for Muco-Obstructive Lung Diseases, Project II: Mucus Obstructed Mice for Biomarker and Drug Development

The major goals of this project are (1) to test in vivo the novel biophysical/biochemical formulation of a “two-gel” mucus clearance system, focusing on the durability of the response to inhaled hypertonic saline, (2) utilizing  $\beta$ ENaC mouse lines of differing airways  $\text{Na}^+$  transport/airway surface dehydration, search for in vivo mucus biomarkers denoting the pharmacodynamic activities of drugs and identify novel “downstream” markers of muco-obstructive/dehydration-induced pathogenesis, e.g., inflammatory cell and epithelial cell markers, (3) test the hypothesis that secreted mucins (MUC5AC, MUC5B) or transmembrane tethered mucins (MUC1, 4, 16) are therapeutic targets with favorable risk:benefit ratios by genetic studies of MUC5AC and MUC5B -/-crosses with  $\beta$ ENaC mice; and (4) test the hypothesis that bacterial infection of mucus-obstructed COPD airways can be prevented or reversed by inhaled hydration/mucolytic therapies.

Role: Co-Investigator

5 P50 HL 120100-05 (Tarran)

9/19/13-6/30/18

NIH/NHLBI

The Impact of Tobacco Exposure on the Lung's Innate Defense System, Project 3: Mouse Models of Human Smoking-related Diseases: What is the Best Mimic of Human Disease?

The major goal of the overall P50 is to measure the potential adverse impact of tobacco alternatives (“little cigars” and Hookah) on the lung's innate defense system. Project 3 proposes development of a novel animal model of smoke exposure that more closely mimics the chronic bronchitis phenotype seen in humans with COPD. This model will be used to validate tobacco exposure biomarkers seen in Projects 1 and 2 as well as to determine epigenetic changes following in vivo exposure to alternative tobacco.

Role: Co-Investigator

4 R01 HL 117843-04 (Harris/Knowles/O'Neal)

7/15/13-5/31/18

1.20 calendar

Case Western Reserve Univ (sub on NIH/NHLBI)

\$137,869 (sub only)

Mining open chromatin to define molecular mechanisms of CF modifier genes

The goals of this project are to define important mechanistic links between genetic variation and severity of CF lung disease and offer opportunity for therapeutic insights. This application focuses specifically on a region of chromosome 11 between the two genes, *EHF* and *APIP*, that shows strong genetic association to cystic fibrosis lung disease severity.

Role: MPI

1 R43 HL 132646-01 (Isaacman/Esther)

4/1/16-12/31/17 (nce)

PHD Biosciences, SBIR sub on NIH

A Targeted Drug for the Treatment of Inflammation in Cystic Fibrosis Lung Disease

The goal of this Phase I SBIR is to examine the potential of an MTAP inhibitor as a therapeutic for CF using a mouse model of CF airways disease. We will test the effects of different single dose concentrations as well as longer term (7-day) treatment on multiple outcome measures including airway and systemic levels of inflammatory cells (neutrophils, macrophages), inflammatory markers (KC, MIP2, LIX), and methionine salvage pathway metabolites (MTA, polyamines). We will also assess the impact of treatment on macrophage activity and lung histology. The primary goal of this proposal is to identify the minimum efficacious dose and determine the pharmacological benefits of a repeat dosing schedule.

Role: Co-Investigator

None Assigned (Couper)

8/1/16-9/30/17

COPD Foundation

SPIROMICS Bridge Funding

1/26/2022

The CSCC will serve as the Data Coordinating Center (DCC) for the SPIROMICS Bridge project. The DCC is responsible for maintaining study documents and the data entry system. We will be retrieving data from the data entry system and creating reports, data checks, and analysis datasets. The DCC is also responsible for site training and certification as well as IRB tracking.

Role: Co-Investigator

4 P01 HL 110873-05 (Boucher) 5/15/12-4/30/17 3.70 calendar  
NIH/NHLBI \$141,351 (Core B)  
Pulmonary Surface Liquid Homeostasis, Core B: Molecular Biology Core

The major goal of this core is to provide molecular services to the projects of the PPG: cloning, RNA expression analysis and siRNA development, and transgenic mouse development and mouse genotyping.

Role: Core Leader

5 R01 HL 103940-05 (Kesimer) 7/21/10-4/30/17 (nce)  
NIH/NHLBI

The Role of Mucin-Protein Interactions in the Innate Defense of the Lung

The goals of this project are 1) To determine our target panel of proteins that show evidence of specific mucin binding; 2) To determine the domains required for the mucin-protein interactions and 3) To assess the effects of mucin-protein interactions on the surface and bulk rheological properties of the mucus. If the goals of this proposal are achieved, they will increase our knowledge and understanding of the relationship between protein composition and the function of airway secretions. Such knowledge is an essential pre-requisite for informed therapeutic intervention.

Role: Co-Investigator

Research Contract (O'Neal) 11/3/15-9/30/16 0.12 calendar  
Spirovation \$16,000  
Target Validation using CRISPR/Cas9 Technology

The goal of this contract to test target compounds on cell cultures for influence on correction of deltaF508-CFTR.

Role: PI

HHSN268200900020C (Couper) 2/1/09-7/31/16  
NIH/NHLBI

SPIROMICS - Genomics and Informatics Center

The major goals of this contract are to establish at UNC-Chapel Hill the Genomics and Informatics Center for the Subpopulations and Intermediate Outcome Measures in COPD study (SPIROMICS) and to serve in this capacity for the course of the study.

Role: Co-Investigator

5 R01 HL 068890-13 (Knowles) 8/1/12-6/30/15  
NIH/NHLBI

Gene Modifiers in CF Lung Disease

The major goal of this project is to test the hypothesis that identification of genetic modifiers of CF lung disease will help to clarify disease pathogenesis and suggest therapeutic targets.

Role: Co-Investigator

R026-CR11 (Boucher) 7/1/11-6/30/15 0.6 calendar  
Cystic Fibrosis Foundation \$162,500 (Core E)  
Epithelial Function in Cystic Fibrosis, Core E: Molecular Biology and Mouse Core

1/26/2022

The major goal of this core is to provide molecular biology materials, technical expertise and training and genetically modified mice relevant to cystic fibrosis research. These materials and support will further research efforts into CF within UNC and also by outside collaborators.

Role: Core Leader

5 P30 DK 065988-10 (Boucher) 4/27/09-3/31/15\* 1.2 calendar  
NIH/NIDDK \$83,390 (Core C)  
Molecular Therapy Core Center, Core C: Molecular Biology and Mouse Core

The major goal of this core is to support the gene transfer community by providing mouse models relevant to cystic fibrosis gene transfer and access to molecular biology equipment and expertise. \*4/1/14-3/31/15 is bridge funding.

Role: Core Leader

Early Excellence Grant (Ribeiro) 7/1/10-6/30/13  
American Asthma Foundation  
IRE1 $\beta$ -Dependent Airway Mucin Production and ATP Release: A New Pathway in Asthma

The major goal of this project is to test the hypothesis that IRE1 $\beta$  is required for mucin production by airway mucous cells, it stimulates mucin transcription and/or regulates genes involved in mucin production or glycosylation, its overexpression potentiates mucin production, and it regulates airway ATP release by regulating the ATP content in mucin granules.

Role: Co-Investigator

5 R01 HL102371-03 Subcontract (Gaggar) 7/2/10-5/31/13 0.6 calendar  
UAB subcontract on NIH grant \$23,000 (sub only)  
A Novel Proteolytic System of Pulmonary Inflammation

The goal of this project is to use the expertise of UNC-CH investigators with regards to the Scnn1b-transgenic over-expressing mouse model along with the UAB group's expertise on the prolylendopeptidase pathway, which is thought to be a novel regulator in pulmonary neutrophilic inflammation, to study the potential for the praline-glycine-proline (PGP)-containing sequences, found to be chemotactic for neutrophils, as a pathway in pulmonary disease.

Role: Subcontract PI

5 R01 HL 095396-04 (Knowles/Wright) 9/24/08-7/31/12  
NIH/NHLBI  
Molecular Phenotypes for Cystic Fibrosis Lung Disease

The major goal of this project is to study the role of gene expression variation in CF lung disease and the integrated analysis of SNPs/CNVs and expression data.

Role: Co-Investigator

5 P01 HL 034322-25 (Boucher) 2/1/07-1/31/12 4.80 calendar  
NIH/NHLBI \$139,833 (sub only)  
Pulmonary Epithelia in Health and Disease, Core B: Molecular and Protein Core

The major goal of this core is to provide Molecular Biology and Protein services to the PPG projects including cloning, RNA expression analysis and siRNA development, and transgenic mouse development and mouse genotyping.

Role: Core Leader

HIRSH0110 (O'Neal) 6/1/10-7/31/11 0.60 calendar  
Cystic Fibrosis Foundation \$40,000  
Feasibility of Na<sup>+</sup> Channel Blocker Therapy for CF

1/26/2022

The major goal of this project is to test the hypothesis that the duration of action of Na<sup>+</sup> channel blockers is influenced by their affinity towards Na<sup>+</sup> channels and the rate of absorption by the airway epithelium.

Role: PI

R026-CR07 (Boucher) 7/1/07-6/30/11 0.60 calendar  
Cystic Fibrosis Foundation \$152,474 (sub only)  
Epithelial Function in Cystic Fibrosis, Core E: Molecular Biology and Mouse Core

The major goal of this core is to provide molecular biology materials, technical expertise and training and genetically modified mice relevant to cystic fibrosis research. These materials and support will further research efforts into CF within UNC and also by outside collaborators.

Role: Core Leader

Subcontract on 3 P40 RR 016049-09S1 (Donahue) 7/1/09-6/30/10 1.20 calendar  
NIH/NCRR subcontract from Jackson Labs \$175,000  
Development of the bENaC Model of Cystic Fibrosis for Translational Research

The major goal of this project is to develop and improve the *Scnn1b* mouse, an existing mouse model of cystic fibrosis (CF), for use in translational research and preclinical drug test protocols. The *Scnn1b* mouse represents an ideal animal model to both identify novel modifier genes and pathways of CF lung disease and to demonstrate the effect of genetic background on preclinical outcomes, paving the way for improved protocol design.

Role: Subcontract PI

RANDEL07P0 (Randell) 3/1/07-6/30/09 (NCE)  
Cystic Fibrosis Foundation  
Dysregulated Airway Physiology in Scnn1b Transgenic Mice

The major goal of this core is to elucidate key mechanisms by which defective mucus clearance results in chronic airway injury by 1) studying the interaction between tethered and secreted mucins to examine mechanisms of mucus adhesion, plaque formation and airway obstruction, 2) determining causes and effects of airway inflammation and goblet cell metaplasia in Scnn1b mice, and 3) examining the pathogenesis of respiratory virus-induced airway disease in Scnn1b mice.

Role: Co-Investigator

R026-CR07 (Boucher) 7/1/07-6/30/09 0.30 calendar  
Cystic Fibrosis Foundation \$40,000 (sub only)  
Epithelial Function in Cystic Fibrosis, Project 2: Transmembrane Mucin Function in Mucociliary Clearance

The major goal of this project is to test the hypothesis that in the dehydrated environment of a CF lung, the secreted mucus sticks to the cells by interacting with mucin molecules, called transmembrane mucins, that are attached to the cell surface, by developing a mouse model deficient for the transmembrane mucin Muc 16.

Role: Project Leader

ONEAL07G0 (O'Neal) 4/1/07-3/31/09 1.80 calendar  
Cystic Fibrosis Foundation \$90,000  
CF Modifiers Defined by Scnn1b Over-expressing Mice

The major goals of this project are to (1) evaluate the strain dependent differences with respect to survival, lung pathology, and inflammatory status by studying these phenotypes in congenic inbred lines of Scnn1b over-expressing mice, (2) document and characterize the short-circuit current between lines and among strains in both tracheal and bronchial tissues, and (3) begin to define the modifying effects between the two lines and strains at a genetic level by establishing an F2 recombinant panel of DNA's for genetic linkage

1/26/2022

studies and by cloning the transgene insertion site for line 6047, which is hypothesized to be linked to modifying locus.

Role: PI

5 R01 HL 080322-04 (Randell) 4/1/05-3/31/09

NIH/NHLBI

Airway Epithelial Adaptation to Infectious Stimuli

The goal of this project is to test the hypothesis that adaptation is a key determinant of airway inflammation and that underlying mechanisms can be exploited as novel approaches for anti-inflammatory therapy.

Role: Co-Investigator

5 P30 DK 065988-05 (Boucher) 4/1/04-3/31/09 1.20 calendar

NIH/NIDDK

\$94,621 (sub only)

Molecular Therapy Core Center, Core C: Molecular Core

The major goal of this Core is to provide a mouse with CF-like lung disease (the betaENaC mouse) and toxicogenomics capabilities to the UNC-CH molecular therapeutics community.

Role: Core Leader

5 P50 HL 060280-10 (Boucher) 9/16/03-8/31/08 1.20 calendar

NIH/NHLBI

\$157,297 (sub only)

SCOR in Airway Biology/Pathogenesis of Cystic Fibrosis, Core B: Molecular Biology and Monoclonal Antibody Core

The major goal of this core is to provide centralized facilities for development of molecular and monoclonal antibody reagents and services as required for SCOR projects.

Role: Core Leader

5 P30 DK 065988-04 (Boucher) 4/1/06-3/31/08 0.60 calendar

NIH/NIDDK

\$43,314 (sub only)

Molecular Therapy Core Center, Project 6: Interfering RNA for Modulation of ENaC Function

The major goals of this pilot project are to generate small interfering RNA to  $\alpha$ ENaC to study the role of ENaC in CF well-differentiated human airway cultures and in the development of CF disease, and to generate a murine model to evaluate loss of ENaC function *in vivo*.

Role: Project Leader

R026-CR02 (Boucher) 7/1/02-6/30/07 0.60 calendar

Cystic Fibrosis Foundation

\$101,537 (sub only)

Epithelial Function in Cystic Fibrosis, Core F: Molecular Core

The major goal of this core is to provide molecular services and analysis to CF investigators.

Role: Core Leader

OSTROW04G0 (Ostrowski) 4/1/05-3/31/07

Cystic Fibrosis Foundation

The Minimal Level of CFTR Necessary for Correction of ENaC Function *in Vivo*

The major goal of this project is to use an inducible, cell-type specific promoter to express different levels of normal mouse CFTR protein in the airways of CF mice to determine in both *in vivo* and *in vitro* models the amount of CFTR protein needed to correct the sodium absorption defect in CF.

Role: Co-Investigator

5 P01 HL 034322-20 (Boucher) 4/1/01-3/31/07 (NCE) 2.4 calendar

1/26/2022

NIH/NHLBI \$144,444 (sub only)  
Pulmonary Epithelia in Health and Disease, Core B: Molecular and Protein Core

The major goal of this Core is to provide a centralized facility for development of molecular reagents and antibodies required for the projects within the Program Project "Pulmonary Epithelia in Health and Disease", including vector construction, production of tagged proteins, protein expression, synthesis and analysis of antibodies, RNA analysis, and maintenance of cDNA clones and cloning of cDNA sequences.

Role: Core Leader

MALL03G0 (O'Neal) 9/1/04-8/31/06 1.2 calendar  
Cystic Fibrosis Foundation \$159,120  
Chronic Pseudomonas aeruginosa Infection Model in Sodium Hyperabsorbing Mouse

The major goal of this project is to develop a mouse model for chronic lung infection with Pseudomonas aeruginosa and other CF related pathogens. We will test the hypothesis that chronic Pseudomonas aeruginosa infection of beta-ENaC transgenic mice requires (1) chronic bacterial exposure with Pseudomonas aeruginosa, and/or (2) co-infection with respiratory viruses and/or other bacterial CF pathogens like Staphylococcus aureus or Haemophilus influenzae.

Role: PI

5 P01 HL 066973-05 (Samulski) 9/30/01-7/31/06  
NIH/NHLBI  
Gene Therapy for Pulmonary & Hematologic Disorders, Project 3: Extra Cellular Barriers to Gene Transfer in the Lung

The major goals of this project are to investigate (1) whether the transported mucus layer is a vector barrier, (2) identification of the components of the glycocalyx of human bronchial epithelia *in vitro* that act as a barrier to gene transfer, and (3) whether mouse models can be used to evaluate the role of the glycocalyx as a barrier to gene transfer *in vivo*.

Role: Co-Investigator

5 R01 HL 070199-04 (Ostrowski) 4/1/02-3/31/06  
NIH/NHLBI  
A Ciliated Cell-Specific Promoter for Gene Therapy of CF

The major goal of this project is to develop a ciliated cell-specific promoter that will improve the effectiveness of gene therapy for cystic fibrosis.

Role: Co-Investigator

RIBEIR03FG0 (Ribeiro) 1/1/04-12/31/05  
Cystic Fibrosis Foundation  
Azithromycin Effect on Airway Epithelial Gene Transfer

The major goals of this project are to evaluate the effect of azithromycin on the inflammatory response of normal airway epithelia triggered by acute *in vitro* mucosal SMM exposure, and to evaluate the effect of azithromycin on the inflammatory response of CF airway epithelia chronically exposed *in vivo* to airway bacterial infection during the course of disease.

Role: Co-Investigator

5 R01 HL 58342-08 (Johnson) 5/1/01-4/30/05  
NIH/NHLBI & NIDDK  
Enhanced Gene Transfer to Lung Epithelia

The major goals of this project are to (1) characterize the intercellular junctional proteins in respiratory epithelia, (2) identify rapidly acting reversible agents that modulate paracellular permeability and determine

1/26/2022

their mechanism of action, and (3) use regulators of junctional permeability and agents that stimulate surfactant uptake to enhance gene transfer to respiratory epithelia by a variety of gene transfer vectors.  
Role: Co-Investigator

ONEAL00V0 (O'Neal) 3/1/01-2/28/05 (NCE) 1.8 calendar  
Cystic Fibrosis Foundation \$406,001  
CF Therapeutic Targets Revealed by Expression Arrays

The major goal of this project is to identify novel therapeutic targets for CF lung disease by using gene expression arrays to reveal genes important in the pathogenesis of CF.  
Role: PI

S880 (Boucher) 12/1/01-11/30/02 0.6 calendar  
Cystic Fibrosis Foundation \$50,000 (sub only)  
Gene Therapy Center, Project XV: Evaluation of Helper-dependent Adenoviral Vectors for Delivery to Lung Epithelium

The major goals of this project are to study the role of the protein MUC4 in the prevention of gene transfer vector introduction by generating mice lacking MUC4 and testing gene transfer in them.  
Role: Project PI

R026 (Boucher) 3/1/00-6/30/02 1.8 calendar  
Cystic Fibrosis Foundation \$106,550 (sub only)  
Core F: Molecular Core

The major goal of this core is to provide molecular services and analysis to CF investigators.  
Role: Core Leader

S880 (Boucher) 12/1/99-11/30/01 0.6 calendar  
Cystic Fibrosis Foundation \$50,000 (sub only)  
Gene Therapy Center, Project III: MUC4 as a Barrier to *In Vivo* Gene Transfer

The major goals of this project are to study the role of the protein MUC4 in the prevention of gene transfer vector introduction by generating mice lacking MUC4 and testing gene transfer in them.  
Role: Project Leader

ONEAL00I0 (O'Neal) 4/1/00-3/31/01 3.0 calendar  
Cystic Fibrosis Foundation \$40,000  
In Vitro Cell Models for CFTR Expression

The major goal of this project is to provide flexible, reliable systems for introducing wild-type and mutant CFTR genes into a variety of relevant *in vitro* culture models.  
Role: PI

5 R21 DK 53927-02 (O'Neal) 8/1/98-7/31/00 7.2 calendar  
NIH/NIDDK \$100,000  
Large Deletion Adenoviral Vectors for Cystic Fibrosis

The major goal of this project is to develop improved vectors for use in clinical trials for cystic fibrosis gene therapy.  
Role: PI

## 8) Service

1/26/2022

2020-present	Cardiovascular and Respiratory Sciences Integrated Review Group, Ad-Hoc Reviewer
2020-present	NHLBI LCMJ Study Section, Permanent Member
2020-present	Co-Chair, Cystic Fibrosis Foundation Path to a Cure Review Panel
2020-present	Chair, PreCISE Network (NHLBI) Quality Control and Biospecimens Committee
2019-present	NHLBI, F10A-K Fellowship Review Panel, Ad Hoc Reviewer
2019-present	Advisory Committee, Cystic Fibrosis Foundation Animal Core
2018-present	Chair, Biospecimen and Biomarker Committee, NHLBI PreCISE Trial Network
2012-present	Chair, Biomarker Working Group and Ancillary Studies Committee, SPIROMICS
2018	NHLBI LCMJ Study Section Ad-Hoc Reviewer
2015-2018	NHLBI K99 Study Section, Permanent Member
2010-2012	NHLBI K99 Award Study Section Ad-Hoc Reviewer
2004-2007	NHLBI SBIR Study Section Ad-Hoc Reviewer

## 9) Research Statement

As an undergraduate at North Dakota State University, I trained in the basics of disease pathogenesis and genetics related to agriculture. The focus on agriculture in these early years stemmed from my love of the farm and my love of farmers. My switch from agricultural to “medical” sciences developed over time as I realized my desire to study cystic fibrosis (CF), which was devastating to my own siblings. This new understanding led me to pursue my PhD in Human and Molecular Genetics. I was accepted as a PhD candidate at Baylor College of Medicine, now one of the premier institutes in the country tackling this topic, under the direction of Dr. Arthur Beaudet. During this time, I transitioned into a large and competitive Howard Hughes Medical Institute funded laboratory. In retrospect, my training at NDSU was excellent. It provided me a very solid background in disease pathogenesis and genetics, and I thrived in Dr. Beaudet’s laboratory. I was able to come out of it a well-trained molecular geneticist capable of technically working with animal models, DNA, and RNA.

At the time of my move to North Carolina, I was focused on gene therapy for CF in my postdoctoral work, following the development of one of the first mouse models for CF and some interesting human genetics related to the F508del mutation as my PhD dissertation. Throughout my training, I was aware of the work of the Cystic Fibrosis Research and Treatment Center (now the Marsico Lung Institute) directed by Dr. Richard Boucher. The work of this group in CF disease pathogenesis was (and still is) world-renowned. Again, by luck or fate, and the help of great people, I was introduced to Dr. Boucher through Dr. Beaudet. Modern molecular biology, with the advent of cloning and polymerase chain reaction and next-generation sequencing, was at its blossoming stage, and my training nicely complemented the skills of the faculty (physiology/cell biology) at the Center at the time. I took on a role as “resident molecular biologist,” which morphed into Director of the Molecular Biology and Animal Models Core, a position that I still hold today. I acknowledge my colleague, Dr. Alessandra Livaraghi-Butrico, who now thankfully serves as Co-Director of the Animals Models side of the Core.

As a Core Director, I am working with the top CF researchers. Through the years, I have been able to participate in a wide array of research efforts, often on the periphery, but always with appreciation. I hope that a brief review of the titles of the papers for which I serve as co-author provides a sense of the breadth of the years. In short, I have worked to develop and/or phenotype a number of animal models (over 20 at last count), introduce the Center to new techniques (from PCR, to quantitative PCR, to RNA/DNA microarrays, and now to single-cell RNA sequencing and spatial transcriptomics) that have been successfully applied to multiple manuscripts and research projects. The efforts of the Core have supported multiple grant applications and trained a constant stream of new post-docs, fellows, technicians, and students throughout the last 20-plus years. My hope through all of this is that I have played some small part in the incredible success the field as a whole, which has seen a dramatic increases in life span and quality of life brought about by modulator therapies. When I started in CF research, the goal was to make progress. What has been accomplished instead are massive gains. The humbling reality is that treatments available today would have allowed my own

1/26/2022

siblings to survive and live productive lives. I have been extremely lucky to have been a small part of this progress.

Another defining feature of my research career has been the expansion of research interests beyond CF. This of course has everything to do with the Marsico Lung Institute and its incredible faculty who have far-reaching research interests beyond CF, to include asthma, COPD, bronchiectasis, bronchopulmonary dysplasia, primary ciliary dyskinesia, and (of relevance today) respiratory pathogens (including viruses and SARS-CoV-2). What I have learned is that what is on the forefront of CF biology and physiology is often on the forefront of respiratory biology, and what is learned in CF can often apply to a multitude of disease situations, providing an opportunity for even broader impact. Thus, we see that cigarette smoking affects CFTR function; mucus accumulation in the CF lung brought about by loss of CFTR affects patients with asthma and bronchitis in similar ways; disease manifestations related to airway inflammation/infection and alterations in physiology seen in CF lung disease apply across a multitude of respiratory conditions. As the connections keep growing, through my interactions with large cohorts, such as SPIROMICS (COPD) and PreCISE (asthma) the impact becomes exponential and the opportunities for understanding compound. SARS-CoV2 has recently provided another opportunity for important collaborations where my input has been of some value. The challenge moving forward, as it has been in the past, is “keeping up” with the technology and the insights it provides – never a dull moment.

### **10) Teaching Statement**

As a research scientist in a clinical institute, I do not have any formal teaching responsibilities. My teaching, then, involves training. One of the primary purposes of the Core is to train in molecular biology methods and the use of mouse models. The training occurs in the environment of regular lab meetings, departmental seminars, manuscript preparation, grant support, and one-on-one meetings with postdocs, faculty, and associated staff. For non-faculty trainees, my philosophy is to generate independent research scientists capable of running their own projects with high integrity. For faculty, it is important to help integrate methods into ongoing research efforts. High scientific rigor and careful consideration of experimental design is a goal, coupled with an appreciation for the benefits and risk of each method. In addition, it is important to me to disseminate the information as much as possible by encouraging publication and public presentation of data. It is hoped that my efforts to teach and train are producing high quality manuscripts that stand the test of time and highly successful independent scientists who are careful thinkers and doers. Formally, I have taken my turn to lead, and present at, the departmental seminar series have run the Animal Models research meeting. In these types of settings, my ability and willingness to teach is hopefully apparent.

### **11) Diversity Statement**

I have not been directly involved in formal DEI activities. I do actively seek to promote a positive, inclusive learning/working environment within my laboratory for the staff, trainees, and students. We provide our Core services without regards to individual characteristics or beliefs, and we base the provision of these services purely on scientific interest and necessity within our resource limitations. All staff are expected to undergo the necessary DEI training and are encouraged to participate in DEI activities. The excellent communication that our administrative staff provides leads to seamless communication of all university and School of Medicine DEI-focused activities to the staff, which provides the necessary awareness. On the peer review side, we as reviewers are asked to evaluate grants and manuscript proposals for inclusion of diverse populations to ensure that, as much as possible and scientifically reasonable, diverse populations (children, women, and minorities) are included in research studies. This is critical for scientific equity, and it is one of the important aspects of my personal reviews. As an employer, I have had the great privilege of supporting a diverse employee base throughout the years, and I am grateful to have worked with them all.